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ABBREVATION 
ACHE  acetylcholine 
ALS  amyotrophic lateral sclerosis 
BNT  Botulinum neurotoxin 
BNT-A Botulinum neurotoxin A 
CFU  colony forming unit 
CP  cerebral palsy 
CT  computed tomography 
EEG  electroencephalography 
MAO-B Monoamine oxydase B 
MDS-UPDRS Movement Disorders Society – Unified Parkinson’s Disease 
Rating Scale  
MRI  magnetic resonance imaging 
ml  milliliter 
PD  Parkinson’s disease 
PIGD  postural instability and gait disorder 
SD  standard deviation 
U  unit 
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1. INTRODUCTION 
Intrasalivary gland injections of Botulinum neurotoxin type A (BNT-A) are 
effective in the treatment of drooling in patients with neurological disorders 
(Şen et al., 2015; Jost, 2016; Restivo et al., 2018). Drooling is a disruption of 
the co-ordinated control mechanism of orofacial and palatolingual musculature 
leading to excessive pooling of saliva in the anterior of the mouth resulting int 
the inadequate drainage of saliva from the mouth (Hussein et al., 1998; Basciani 
et al., 2011). Sialorrhea is a common symptom of different neurological 
disorders, such as cerebral palsy (CP) in children (Gonzalez-L et al., 2017) and 
amyotrophic lateral sclerosis (ALS) (Benson et al., 2007) and Parkinson’s 
disease (PD) in adults (Odachi et al., 2017). In these neurological conditions, 
sialorrhea is usually associated with incomplete lip-closure, tongue protrusion, 
slow and stiff tongue movement, lack of voluntary control of jaw and tongue, 
and oral dyskinesia (Tahmassebi et al., 2003; McGeachan et al., 2017). 
Sialorrhea may also be caused by intraoral sensitivity disorder next to oral 
motor dysfunction and dysphagia (Dias et al., 2016). Furthermore, it may be a 
side-effect of treatments that increase the action of acetylcholine in the body 
(Layton et al., 2014). 
Fiberoptic endoscopic evaluation of swallowing is suggested in the early 
stage of sialorrhea to evaluate dysphagia, the risk of aspiration and also to 
collect important data to help with therapy selection (Warnecke et al., 2010; 
Steffen et al., 2013).  
BNT injections are a valuable treatment for many therapeutic indications: 
treatment of spasticity and dystonia, sphincter disturbances, paralysis of facial 
nerves, facial spasms, blefarospasm, strabismus, atypical headaches, bruxism, 
“gummy smile,” Frey’s syndrome, allergic rhinitis, excessive tear flow, etc. 
(Brin, 2009; Majid, 2010; do Nascimento Remigio et al., 2015; Rallmann et al., 
2016; Zhang et al., 2017; Al-Fouzan et al., 2017). Treatments for sialorrhea 
include also salivary gland botulinum toxin next to anticholinergic drugs, 
surgery, salivary gland-targeted radiotherapy, and rehabilitation (McGeachan et 
al., 2017; Chaléat-Valayer et al., 2016). Although BNT-A can effectively treat 
sialorrhoea, its effect on salivary characteristics, including the amount of 
cariogenic bacteria, was not investigated. 
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2. REVIEW OF THE LITERATURE 
2.1. Neurological disorders that cause sialorrhea 
2.1.1. Parkinson’s disease 
PD is a slowly progressive neurodegenerative movement disorder, with tremor, 
rigidity, and bradykinesia as its main motor symptoms. The onset of PD usually 
occurs after the age of fifty, and its prevalence increases with age. Its patho-
physiological mechanisms are related to the degeneration of dopaminergic 
neurons in the substantia nigra of the brain (Poewe et al., 2017). There are 
multiple pathways of pathogenesis in PD: α-synucleinproteostasis, mitochond-
rial function, oxidative stress, calcium homeostasis, axonal transport, and neuro-
inflammation (Poewe et al., 2017). It has been speculated that the cause of PD 
could be external, such as microbial, which could trigger the pathologic process 
in the corresponding organs, subsequently spreading to the central nervous 
system (Pereira et al., 2017). 
The most common manifestations of PD are: resting tremor, slow reactions 
and responses, gait instability and short scuffy steps, lack of facial expression, a 
reduced blinking rate, a quiet monotone voice, dysartria, dysphagia, and 
sialorrhea (Kadastik-Eerme et al., 2016; Poewe et al., 2017). Hyposmia, 
rigidity, and involuntary jaw movements with orofacial pain may occur in PD 
patients. (Bakke et al., 2011; Adler et al., 2016). Among the non-motor symp-
toms of PD, sialorrhea is one of the most disabling and embarrassing for 
patients (Marras et al., 2016; Schirinzi et al., 2017). 
According to the Hoehn and Yahr scale, PD is divided into five stages 
(Hoehn and Yahr, 1967). Stage 1 means mild disease and only one side of the 
body is affected, usually with minimal or no functional impairment. Stage 2 
affects both sides of the body but posture and balance remain normal. In stage 3 
both sides of the body are affected and there is some imbalance when standing 
or walking; it is also called moderate disease. Stage 4 is classified as advanced 
disease and affects both sides of the body with standing or walking problems 
requiring constant help and caregiving at home. Stage 5 is fully developed 
severe disease with restriction to a bed or wheelchair. 
The pharmacotherapy of Parkinson’s disease includes levodopa, dopamine 
agonists, inhibitors of monoamine oxidase (MAO-B) and catechol-o-methyl-
transferase (COMT), and amantadine (Oertel et al., 2016). Later in the course of 
the disease, motor complications may appear. The standard medication of PD is 
levodopa, which stimulates the remaining neurons in the basal ganglia and 
modifies into dopamine, thereby promoting synaptic transmission and im-
proving function. Depending on the stage, different oral formulations of levodopa 
or dopamine agonists with a long half-life, administered through transdermal 
application or parenteral pumps for continuous drug supply, are determined 
(Taba et al., 2008). Levodopa’s effect decreases with time, and after 5–10 years 
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of treatment at least half of the patients become partially unresponsive to the 
medication. There is still a degree of clinical uncertainty about when to initiate 
levodopa (Giladi et al., 2016). A combination of different drugs is commonly 
used. Dopamine receptor agonists are commonly used as first-line monotherapy 
for symptomatic control in the early stages of PD to delay the initiation of 
levodopa therapy. Also, it is used as an adjunctive therapy to levodopa when the 
disease progresses (Giladi et al., 2016). Treatment can lead to severe side 
effects, including dyskinesia of the head, face, and tongue, xerostomia, and 
dental attrition (Poewe et al., 2017). 
There is evidence that drooling relates to PD pharmacotherapy and the stage 
of the PD (Bagheri et al., 1999; Tumilasci et al., 2006; Fereshtehnejad et al., 
2017). Usually, there is a bigger problem with hyposalivation and xerostomia 
instead of excessive saliva flow in elderly patients and in PD patients. Approxi-
mately 30% of those aged sixty-five years and older are affected with hypo-
salivation, which is a consequence of systemic diseases, medications, and head 
and neck radiotherapy (Gupta et al., 2006). Usually, hyposalivation poses a 
higher risk for normal oral function and health than hypersalivation (Gupta et 
al., 2006). In PD patients, drooling is a delayed complaint and generally affects 
men twice as often as women (Postuma et al., 2015). Diurnal and nocturnal 
drooling are differentiated. Diurnal drooling is a complaint in about 28% of PD 
patients. It typically appears later in the disease’s course and is associated with 
involuntary mouth opening and swallowing dysfunction due to weak muscu-
lature (Nutt, 2016). Nocturnal drooling appears with or without diurnal drooling 
in 58% of PD patients (Zlotnik et al., 2015). Drooling is treated with 
pharmacotherapy, including intraglandular BNT-A injections (Bruno et al., 
2016).  
 
 
2.1.2. Amyotrophic lateral sclerosis 
ALS is a progressive neurodegenerative motor neuron disease with a terminal 
outcome with an incidence of ~2.16 per 100,000 person-years (Riva et al., 
2016). Its prevalence is lowest in younger people (0.5 per 100,000 in those 
between 18 and 39 years old), and highest (20.0) among persons aged 70–79 
years. The ratio of cases in males to females was 1.7:1 (Mehta et al., 2018). The 
mechanism leading to neurodegeneration of motor neurons is not fully 
understood. Loss of different protein function in genes (like C9orf72) and RNA 
toxicity with RNA binding protein sequestration are potential reasons for the 
disease’s generation. The disease causes the death of neurons which control 
voluntary muscles. It causes progressive muscular weakness, leading to death 
by respiratory insufficiency within three to five years (Riva et al., 2016). 
Malnutrition is also a risk factor for death in ALS. No effective curative 
therapies are available. Only one drug (riluzole) was approved in recent years to 
treat ALS; in 2017 a second drug, edaravone was also approved (Mehta et al., 
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2018). However, these can only prolong life by a matter of months. Thus, 
symptomatic and palliative care are usually implemented. 
ALS phenotypes vary depending on the involvement of upper or lower 
motor neurons, the site of onset, and the rate of progression. ALS is charac-
terized by rigid muscles, muscle twitching, and gradual weakening due to 
muscle atrophy. This results in impaired speech, dysphagia, and eventually 
breathing problems (Riva et al., 2016). Drooling is one of the autonomic 
symptoms in ALS. About 50% of patients with ALS have significant disorders 
in the control of saliva (Jackson et al., 2015). ALS may cause dysphagia, as 
well as limb weakness, dysarthria, respiratory failure, and emotional lability 
(Young et al., 2011). There is an increased risk of aspiration pneumonia due to 
increased mucous secretions in the throat and lungs, the inability to swallow 
saliva, and an impaired coughing reflex as a result of weakness and diaphragm 
and respiratory muscle fatigue (Banfi et al., 2015). Patients with ALS often 
have problems with thick and thin secretions coexistence (McGeachan et al., 
2016). Sialorrhea is often treated with pharmacotherapy, including intraglan-
dular BNT-A injections (Manrique, 2005; Jackson et al., 2015). 
 
 
2.1.3. Infantile cerebral palsy 
Cerebral palsy (CP) is a leading cause of physical disability in children with 
motor disorder of variable manifestations. The prevalence of CP is approxi-
mately 1.5 to 2.5 per 1,000 live births (Odding et al., 2006; Reid et al., 2012). 
Children may also have sensory dysfunction (seeing and hearing), cognitive and 
behavioral deficits, and dysfunctional oral motor control. CP leads to abnormal 
movements of the tongue and facial muscles (Liu et al., 2014). While drooling 
is usually considered abnormal in children over four years of age, it has been 
estimated to occur in approximately 10% to 37% of children with CP (Reid et 
al., 2012). Finding a solution to this problem is needed in order to simplify 
caregivers’ work, because in many CP cases children are bedridden and it is 
necessary to periodically wipe up leaking saliva or aspirate excess saliva from 
the pharynx. Sialorrhea is generally caused by difficulty keeping saliva in the 
mouth, by swallowing difficulty, or by overproduction of saliva. Patients with 
drooling are at risk of aspirating saliva, food, or fluids into their lungs, which 
may result in aspiration pneumonia and breathing difficulties if there is a 
problem with gagging and coughing (Jongerius et al., 2004; Chaléat-Valayer et 
al., 2016; van Hulst et al., 2018). Inadequate swallowing and lip closure are the 
main causes of drooling in cases of mental retardation and CP (van Hulst et al., 
2018). If the saliva is not swallowed, a large amount of saliva can be drooled 
from the mouth. 
Oral health is more compromised in mentally disabled children (Radha et al., 
2016; Jan et al., 2016). The oral health status of children with CP was not 
significantly different from that of normally developing children but the oral 
health-related quality of life of children with CP was significantly lower than 
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that of normally developing children (El Ashiry et al., 2016). Children with 
neurological disorders are at increased risk of induced pain. Bourseul et al. 
(2016) conducted a study on pain during daily care activities in children with 
motor disabilities and found that one of the most frequent painful activities was 
mouth care. Children with CP usually need dental treatment under general 
anesthesia or sedation (conscious or deep) carried out in a hospital depending 
on the severity of the main disease (Corcuera-Flores et al., 2014). CP children 
require extra help and rely on their parents or guardians to achieve and maintain 
good dental and oral hygiene (Liu et al., 2014). 
 
 
2.2. Saliva 
Saliva is a secretory fluid responsible for the lubrication of the alimentary tract 
with a mucin-rich film, making chewing and swallowing possible by moistening 
and helping with taste and digestion. It also protects the teeth and the oral and 
esophagus mucosa against viruses, bacteria, and fungi (Proctor et al., 2018). It 
cleans teeth regularly, reduces bacteria, acts as buffer medium, and protects 
hard tissue against acid damage after sugar intake (Llena-Puy, 2006; Proctor et 
al., 2018). The buffer medium in saliva remineralizes the enamel of teeth and 
stimulates wound healing. Saliva also helps in the regulation of oesophageal 
acidity and protects the upper respiratory tract from regurgitated gastric acid-
induced infections. It is also important for speech articulation (Llena-Puy, 
2006). 
Saliva is produced by three major paired glands (parotid, submandibular, and 
sublingual glands) and by minor glands located all over the oral and pharyngeal 
mucosa. 90% of the total saliva is produced by the major glands and 10% by the 
minor glands. The parotid gland is the largest in size but the submandibular 
gland produces the most saliva (Bradley et al., 2011). About 70% of high-
viscosity resting saliva is produced by the submandibular glands; the parotid 
and sublingual glands produce about 25% and 5% of secretions, respectively. 
The parotid glands are responsible for producing great amounts of watery 
enzyme (amylase) containing saliva while eating and drinking (Fejerskov et al., 
2008). The minor glands prevent the feeling of dry mouth, and secrete mucin-
rich saliva (Bradley et al., 2011). 
Saliva contains many components such as calcium, phosphorus, proteins, 
enzymes, and bicarbonates. Saliva’s most important function is to bathe the 
teeth in a supersaturated solution of calcium and phosphorus so that tooth 
enamel is constantly exposed, leading to the replacement of any loss of tooth 
structure due to demineralization. Salivary secretion is regulated and controlled 
by both the parasympathetic and sympathetic autonomic nervous systems; both 
nerve stimulations lead to increased saliva production, but the salivary com-
position is different. During the mastication process, parasympathetic stimu-
lation produces a large volume of low-protein saliva, but in the case of stress 
and high activity, the sympathetic stimulation produces a smaller volume of 
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protein-rich saliva. Higher salivary calcium may act as a risk factor for 
periodontal disease through the threat of raised dental plaque mineralisation 
(Gupta et al., 2016). Compared to age-matched control groups, PD patients 
have a higher concentration of salivary sodium, chloride, and amylase (Tumi-
lasci et al., 2006). 
Salivary flow rate is an indicator that shows the amount of saliva produced 
by salivary glands in a span of time (mL/min). This is divided into stimulated 
salivary flow rate and unstimulated salivary flow rate. Stimulated saliva is 
secreted due to gustatory and masticatory sensory stimulation. Unstimulated 
saliva does not depend on the presence of such stimuli as food or chewing. 
Saliva is also divided into “duct” and “whole” saliva (Proctor et al., 2018). 
Whole saliva consists of duct saliva and as well as secretions of oral, nasal and 
pharynx mucosa. It also contains food derbis, microorganisms, desquamated 
epithelial, and blood cells. The daily production of whole saliva is normally 
0.5–1 liters (Fejerskov et al., 2008; van Hulst et al., 2018). Individuals with 
deviations in salivary flow rate, consistency, and composition are predisposed 
to a higher risk of oral diseases (Radha et al., 2016). Saliva flushes plaque and 
bacteria from oral mucosal and dental surfaces. 
Saliva amount, flow rate, pH, and buffering capacity are significant aspects 
of oral health (Gopinath et al., 2006). Salivary flow pH and buffering capacity 
are factors that influence the risk of dental caries (Liu et al., 2014). 
Saliva pH depends on the secretion rate. Normal salivary pH in a healthy 
individual is about 6.3, varying between 6.0 and 7.5. Most alkaline values are 
obtained under stimulated flow conditions (Fejerskov et al., 2008). When the 
pH of saliva decreases below 5.5, demineralization usually follows. Saliva 
functions to buffer the pH of the oral environment to prevent it from becoming 
too acidic. Buffer capacity is the ability of saliva to protect and repair oral 
mucosa and dental remineralization. This depends on the saliva’s acids and 
bases. Lower levels of salivary pH lead to caries and higher levels lead to dental 
calculus (Sharma et al., 2012). Buffering capacity indicates how quickly oral 
pH can reach its normal value after a meal. Saliva buffering capacity neutralizes 
acids present in the mouth and maintains the mouth’s usual pH after a meal. 
Salivary buffering capacity protects the teeth from dental caries (El-kwatehy et 
al., 2016). Individuals with a high salivary buffer capacity are often caries-
resistant (El-kwatehy et al., 2016). 
Salivary buffering capacity can be attributed to several systems such as the 
phosphate system and the carbonic acid/bicarbonate system. The main 
bicarbonate buffer is effective only at high salivary flow rates. When the acid 
content of saliva increases, the concentration of hydrogen ions also increases 
and thereby lowers the pH. The enzyme carbonic anhydrase found in saliva 
catalyzes the reaction between the free hydrogen ions from the acid and the 
bicarbonate ions. Water and carbon dioxide gas are the end products of this 
reaction which is released from the oral cavity. As more free hydrogen ions 
interact with bicarbonate ions, the pH begins to rise and the saliva begins to 
return to normal pH levels. The buffering capacity of saliva varies from person 
15 
to person. Salivary flow designates the capacity of saliva to buffer against acid. 
The greater the salivary flow is, the more bicarbonate ions are available to 
combine with free hydrogen ions. When acids get into the oral cavity, salivary 
flow is stimulated and increases within minutes. 
Normal salivary flow rates are generally 0.1–0.6 mL per minute. A salivary 
flow rate of less than 0.1 mL per minute is considered low. Without the pro-
tective buffering capacity of saliva, enamel would be demineralized and lost 
(Perkins et al., 2001). However, this buffering capacity of saliva is limited and 
can be overloaded by frequent or long-term exposure to acids. Reduction in 
salivary flow and increase in calcium and phosphate concentration in 
composition promotes calculus formation and periodontal disease (Gupta et al., 
2016). Salivary flow rate and pH are significantly lower in patients with oral 
lesions compared to those without oral lesions (Foglio-Bonda et al., 2017). 
Basal salivary flow rate is measured by collecting unstimulated “whole saliva” 
(Proctor et al., 2018). Whole saliva stays in the mouth fourteen hours per day 
and protects oral tissues. Stimulated salivary flow rate shows the secretion 
during eating and also two hours after food intake. Unstimulated whole saliva 
salivary flow rate is considered to be a more clinically reliable parameter than 
stimulated salivary flow rate. Many diseases can alter oral homeostasis. From 
earlier studies “risk patients” for saliva change are detected. Lichen and 
leukoplakia in oral cavity reduces the unstimulated whole saliva salivary flow 
rate values. It is also known that antihypertensive drugs decrease oral pH. 
Furthermore, cancer or liver disease decrease the unstimulated whole saliva 
salivary flow rate (Foglio-Bonda et al., 2017). 
Low salivary flow (resting time saliva formation < 60 sec. and amount of 
saliva collected in 5 min. < 3.5 mL), highly acidic pH (5.0–5.8), and lower 
values of buffering capacity (0–5) increase the risk of caries. 
 
 
2.3. Sialorrhea 
Sialorrhea is defined as the inability to control oral secretions, resulting in 
excessive saliva accumulation in the oropharynx. Sialorrhea, also called 
“drooling,” “dribbling,” and “drivelling” is the involuntary escape of saliva 
from the mouth. In the literature, sialorrhea, ptyalism and hypersalivation are 
synonymous. To avoid confusion, it is important to distinguish drooling from 
hypersalivation. Hypersalivation is overproduction of saliva and it is swallowed 
without problems. Drooling is normal in growing children up to the age of 
eighteen months (Erasmus et al., 2011; van Hulst et al., 2018). Pathological 
drooling can be a primary symptom but this condition is rare and usually not 
associated with neurological disorders (Hussein et al., 1998; van Hulst et al., 
2018). Cardona et al., (2015) reported that in the pediatric population the 
parotid and submandibular salivary glands do not differ in size between children 
with or without drooling. Drooling as a secondary symptom is caused by 
different neurological disorders like ALS, CP, and PD. 
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Dysregulation of swallowing leads to dysphagia and drooling. Sialorrhea is 
divided into “anterior” and “posterior drooling.” Anterior drooling is the 
unintentional loss of saliva from the mouth leading to negative psychosocial and 
physical consequences. It can produce perioral infections and impaired 
dentition. Posterior drooling is a pharyngeal problem, wherein saliva flows over 
the tongue through the oropharyngeal isthmus and increases the risk of saliva 
aspiration to the lungs. Aspiration in children with CP usually occurs silently 
(without clear coughing or choking) and chronic aspiration of saliva might lead 
to significant lung injury. 
 
 
2.4. Different options for sialorrhea treatment 
Sialorrhea treatment includes anticholinergic drugs, salivary gland botulinum 
toxin, surgery, salivary gland-targeted radiotherapy, and rehabilitation 
(McGeachan et al., 2017; Chaléat-Valayer et al., 2016). 
 
 
2.4.1. Pharmacotherapy 
Anticholinergic medications reduce secretions in the mouth, throat, airway, and 
stomach. They work by blocking the activity of acetylcholine in the body, 
which decreases secretions (Banfi et al., 2015; Harms et al., 2009). (For 
example glycopyrrolate is used in 1–2mg doses 3 times/day; atropine eye drops: 
1–2 drops 4–6 times/day; amitriptyline: 25–50mg at bedtime; scopalamine 
transdermal patch: 0.5 mg every 3 days; hyoscyamine sulfate: 0.125–0.25 mg 
tablet or elixir 4 or 6 times/day; and diphenhydramine: 25–50 mg 3 times/day). 
Oral medication like glycopyrrolate and topical agents are also used, but the 
effect is quite variable (Layton et al., 2014). Intraoral tropicamide films offer 
short-term relief from sialorrhea (Lakraj et al., 2013). Anticholinergic drugs 
cause a thickening of mucous secretion in the throat and lungs, which is a 
dangerous complication. Scopolamine skin patches may result in pupillary 
dilatation, skin reactions, and urinary retention as adverse side effects. 
Anticholinergic drugs are contraindicated in the presence of heart diseases, 
glaucoma, pyloric stenosis, prostatic hypertrophy, and hepatic or renal 
insufficiency (Banfi et al., 2015; Lakraj et al., 2013). 
Antireflux medications also are suggested for use in the case of drooling 
(Lakraj et al., 2013). 
A novel option in the treatment of advanced PD drooling is rotigotine 
patches, a non-ergolinic dopamine agonist with continuous transdermal delivery. 
Schirinzi et al. (2017) observed that rotigotine 4mg/24h dosage significantly 
improved drooling. 
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2.4.2. Botulinum neurotoxin A treatment 
BNT-A injections are suggested as a first-choice treatment for adult sialorrhea 
(Shetty et al., 2006). BNT-A injections are less invasive than surgical treatment 
(i.e. duct ligation of the salivary gland). Different studies have used several 
BNT serotypes (A and B), treatment regimens, and routes of administration 
(direct or transductal approach) with varying outcomes (Banfi et al., 2015). In 
the treatment of sialorrhea, the administration of BNT into salivary glands is the 
most effective way to control saliva flow (Meece et al., 2010; Lakraj et al., 
2013). BNT-A injections are mostly needed in cases of neurological disorders 
(Manrique, et al., 2005). The most frequently treated diseases are infant CP 
(30%), PD (20%), and ALS (15%) (Møller et al., 2011; Fuster-Torres et al., 
2007; Møller et al., 2015). BNT-A injections are effective in about 50% of 
ALS-conditioned sialorrhea cases. However, for many patients, the treatment is 
not enough to decrease salivary flow (Verma et al., 2006). BNT-A injections 
have also demonstrated good results in the treatment of recurrent parotitis, i.e. 
in Sjörgen syndrome (O’Neil LM et al., 2016). 
Researchers have different priorities in their choice of which salivary glands 
should be targeted for treatment. Over half of them injected BNT-A into the 
parotid glands, 9.5% into the submandibular glands, and 38% into both (Fuster-
Torres et al., 2007). The BNT-A injection procedure can be done blindly or 
under ultrasound guidance. As a complication, BNT-A injection may damage 
muscles, arteries, or nerves around the salivary glands, or muscle weakness may 
result in an improper BNT-A injection. The injection can also cause weakness 
in adjacent muscles, resulting in swallowing or mastication difficulties. There is 
a higher failure rate when injecting the submandibular glands blindly compared 
with the parotid glands. To reduce the complication rate, ultrasound guidance is 
suggested (So et al., 2017). The safest way to inject BNT-A blindly, depending 
on the anatomical landmarks, is to inject at the point that is 20%–35% from the 
mandible angle on the inferior view and 1.5 cm below the inferior line of the 
mandible on the lateral view. The needle should be inserted to a depth of 2.0 cm 
from the skin surface (Lee et al., 2010). 
 
 
2.4.2.1. Botulinum neurotoxin 
BNT is produced by the anaerobic bacterium Clostridium botulinum. The 
mechanism of the BNT is based on targeting the release of acetylcholine from 
cholinergic nerve endings, thereby causing paralysis of muscles and/or glands 
(Awan, 2017). There are seven different serotypes of BNT (BNT-A, -B, -C, -D, 
-E, -F, and -G) (Orsini et al., 2015). Only the A and B serotypes are available as 
drugs and used for sialorrhea treatment (Bentivoglio et al., 2015). The toxin is 
isolated, purified, and stabilized in order to be used as a drug. Acetylcholine is a 
neural transmitter that stimulates muscles and the secretion of glands. The 
toxin’s action leads to the blockade of the cholinergic nerves. BNT diffuses into 
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human tissue and binds irreversibly to the presynaptic terminal of the neuro-
muscular or neuroglandular junction and, by cleaving specific membrane pro-
teins, causes acetylcholine excretion. BNT action does not occur immediately. 
The maximum effect can be seen after a few weeks, and the duration of the 
effect varies from 2–6 months (de Maio et al., 2007). The effect of BNT slowly 
decreases over time as the affected axons grow new nerve terminals and restore 
the impaired transmission leading to damaged synapse regeneration (de Maio et 
al., 2007). 
There are three main BNT-A products available: onabotulinum toxin-A 
(Botox®), abobotulinum toxin-A (Dysport®), and incobotulinum toxin-A 
(Xeomin®) (Jost et al., 2015; Scaglione, 2016). These toxin brands vary in their 
specific activity, packaging, constituents, excipient, and storage. Dysport® has 
the best cost-efficacy profile (Scaglione, 2016). The concept of calculating the 
dosage units for the different products is not clearly understood. The dosage 
units of different products of Botox® and Dysport® do not relate to each other. 
The ratio fluctuates from 1:1 to as high as 1:11 (Scaglione, 2016). For Botox® 
and Dysport®, the most commonly used ratio is close to 1:2.5–1:3, based on the 
available data from placebo-controlled clinical trials. Xeomin® has a 1:1 ratio 
to Botox®, according to the manufacturer (Scaglione, 2016). Different products 
also have a distinct molecular weight, which is thought to affect the toxin’s 
spread, but this has not been proven. The toxin’s spread to areas away from the 
injection site could be undesirable because this may increase the risk of adverse 
effects. Botox® with the highest complex size of 900 kD is the least diffusible, 
whereas Xeomin® with the 150-kD neurotoxin is the most diffusible. The 
standard dilution for Botox® and Dysport® is 2.5 ml (de Maio et al., 2007).   
 
 
2.4.2.2. Dosages of BNT-A in the treatment of drooling 
The recommended total dosage of BNT-A injections varies from 10–100 U of 
Botox® (onabotulinum toxin-A) or 30–450 U of Dysport® (abobotulinum 
toxin-A), according to different authors (Fuster Torres et al., 2007). Reduced 
production of saliva was observed following these injections, and the duration 
of the therapeutic effect was 1.5–6 months (Fuster Torres et al., 2007). The total 
dose of onabotulinum toxin-A (Botox®) recommended for salivary gland 
injections varies from 60 to 250 U. 20 to 100 U is diluted in 0.4 mL of saline 
solution and injected into two sites in each parotid gland and 20 to 25 U is 
diluted in 0.1 mL of saline solution and injected into a single site in each 
submandibular gland (Porta et al., 2001; Breheret et al., 2011; Banfi et al., 
2015). Treatment with lower doses of the onabotulinum toxin-A, with 20 U into 
each parotid gland and 10 U into each submandibular gland, have a proven 90% 
success rate (Porta et al., 2001). It is suggested to start with lower doses, for 
instance 20 U per submandibular and parotid gland bilaterally (total dosage of 
80 U), and raise the dose to 30 U per gland in cases of reinjection (Moller et al., 
2015). There is also a scheme in use with a BNT-A dosage of 0.5 U/kg of 
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onabotulinum toxin-A (Botox®) injected into each submandibular and parotid 
gland under ultrasonographic guidance in children with sialorrhea, which is 
effective in 70.5% of cases (Jeung et al., 2012). Some authors prefer to inject 
only submandibular glands and use a total dosage of 30 U of BNT-A (Shetty et 
al., 2006). Suggested abobotulinum toxin-A (Dysport®, Ipsen Ltd., Slough, 
UK) doses in cases of child sialorrhea to submandibular glands are plotted 
according to the scheme of 1 U/kg/gland (Sidebottom et al., 2013). The study 
with the total dosage of 100 U incobotulinum toxin-A did not give the desired 
result of reducing salivation (Narayanaswami et al., 2016). 
 
 
2.4.2.3. Changes in gland tissue parenchyma after BNT-A reinjections 
Salivary gland atrophy or apoptosis have to be taken into consideration after 
recurrent injections. The anteroposterior distance of a gland is reduced signi-
ficantly after BNT-A injections compared to the control group (Cardona et al., 
2015). The first human study on salivary gland histological findings after  
BNT-A treatment showed no significant difference in the number of acinar cells 
by surface area (Mosseri et al., 2017). 
 
 
2.4.2.4. Complications of BNT-A injections 
Overall, BNT-A injections are considered to be a safe treatment option with 
only minor side effects. However, there are studies describing dysphagia, 
choking, and breathing difficulties with nocturnal coughing due to thickened 
saliva as a complication after BNT-A injection (Layton et al., 2014). Some 
patients complain about reduction in saliva viscosity (12.2%), swallowing 
difficulties (3.1%), temporarily deteriorated feeding behavior (6.1%), and 
xerostomia (1.7%) (Scheffer et al., 2010). There are some suggested measures 
for treating swallowing difficulties due to thickened saliva: pineapple juice as a 
lytic agent, cough assistance, saline nebulisers, and suctioning or mucolytic 
drugs like carbocisteine (McGeachan, 2017). The most frequent complications 
are weakness of adjacent muscles, leading to difficulty swallowing due to an 
incorrect injection of the toxin into the masseter or pharyngeal muscles. Other 
risks include hematoma and injury to the carotid arteries or damage to the facial 
nerve (So, 2017). A high number of postinjection complications (in about 23 
cases out of 69) is also described, including aspiration pneumonia, dysphagia, 
and a decrease in head mobility control in children after BNT-A treatment. 
Eight of them where seriously manifested, requiring hospitalization in five cases 
and insertion of a nasogastric tube in two cases (Chan et al., 2013). 
BNT-B is used for the treatment of drooling as well but the body’s formation 
of neutralizing antibodies against BNT-B appears to be an important obstacle. 
BNT-B gives rise to non-neutralizing antibodies that also cross-react with  
BNT-A (Berweck et al., 2007). BNT reinjections in less than three months is a 
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contraindication as the neutralizing antibodies become evident in such cases 
(Orsini et al., 2015).  
BNT treatment is contraindicated in cases of some relevant neuromuscular 
disorders (like neuromuscular junction diseases, including autoimmune acquired 
myasthenia gravis and Eaton-Lambert syndrome). It is not recommended when 
social and psychological support is missing (Orsini et al., 2015). 
According to the study of Erasmus et al. (2011) 93 children were full 
responders to BNT-A injections while 33 children were unresponsive. 
Nevertheless, despite the positive results with BNT-A injections, there 
remains a threat of compromised oral health through the changes in saliva. 
 
 
2.4.2.5. Sialorrhea treatment in childhood 
Approximately 13% cases of drooling are successfully treated in normally 
developed children while in children with slower development, the success rate 
is 18%. In early childhood, hypersalivation is considered to be a normal con-
dition, but in older children (after 18 months) it may cause social problems 
(Montgomery et al., 2016). 
Treatment with BNT-A is an invasive procedure and usually requires a 
general anaesthetic or sedation in children, depending on their anticipated 
ability to tolerate the procedure. Generally, the injections are performed by oral 
surgeons who locate the glands by palpation or under ultrasound guidance. With 
BNT-A intrasalivary gland injections to treat sialorrhea in neurologically 
dysfunctional children, around 60.4% of cases showed good results, while 
approximately 20.8% had moderate results, and 18.8% showed no improvement 
(Mahadevan et al., 2016). The effect of BNT-A is not related to the severity of 
the disability. Children with severe neurological dysfunction respond to BNT-A 
injections as effectively as their less impaired peers (Mahadevan et al., 2016). 
Improved oral hygiene, including reduction in halitosis, reduced perioral 
dermatitis and improved speech and feeding, is a secondary benefit of the  
BNT-A injection. These effects were gone after eight months when BNT-A’s 
impact wore off (Scheffer et al., 2010). A contraverse study showed that in the 
span of ten years, up to 30 percent of the CP children’s drooling severity and 
frequency did not change significantly after the submandibular BNT-A injection 
(Erasmus et al., 2011). 
 
 
2.4.3. Surgery 
Submandibular gland excisions have been the treatment of choice for sialorrhea. 
One of the most relevant complications is marginal facial nerve paralysis. 
Despite this complication, this type of surgery is safe (Hernando et al., 2012). 
Transcervical procedure approach leads to external scars and is one of the 
reason to decline this surgical. Caregivers’ satisfaction is correlated with the 
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treatment outcome and generally the appearance of scars do not influence 
satisfaction (Delsing et al., 2016). 
Endoscopic transoral neurectomy of the submandibular and sublingual 
glands in the management of drooling in conventional treatment-resistant patients 
has good results in saliva production reduction (Ozturk et al., 2017). 
Wilkie’s original operation (1967) consists of the retropositioning of the 
parotid ducts into the tonsillar fossa region along with bilateral submandibular 
gland resection. These procedures have several variations: transposition, ligation, 
deviation of both submandibular and parotid ducts behind the anterior pillar of 
the soft palate (4-duct diversion); bilateral submandibular duct relocation with 
or without sublingual gland excision; a combination of ipsilateral parotid duct 
ligation and contralateral parotid duct repositioning; and ligation of both parotid 
and submandibular ducts (4-duct ligation). These procedures cannot be 
performed in patients with a history of recurrent aspiration pneumonia, as it 
may increase aspiration risk because it directs saliva posteriorly (Bafiv et al., 
2015; Scheffer et al., 2010). Chronic sialadenitis and transient swelling are 
common complications with surgery (Hussein et al., 1998). 
Surgical relocation of the submandibular gland ducts with removal of 
sublingual glands is effective in 75% of cases. The only complication noted was 
ranula formation (Hornibrook et al., 2012). 
Sectioning of the parasympathetic neural pathway: Chorda tympani resection 
is considered a poor method for reducing stimulated salivary flow (Banfi et al., 
2015). 
 
 
2.4.4. Radiotherapy 
Radiotherapy of the salivary gland has also been an effective method to reduce 
excessive drooling. There are different techniques like electron-based therapy 
and photon-based therapy. Electron-based therapy appears to be better tolerated 
than photon-based therapy. Photon-based therapy may result in acute toxicity 
symptoms (oral pain and mucositis during or immediately after irradiation) or 
delayed reactions (edema or xerostomia one month after irradiation or oral pain 
three months after irradiation). A total dose of 20 Gy is suggested to be 
administered in five intervals, encompassing the whole of the submandibular 
gland and excluding the upper part of the parotid gland. The benefits of 
radiation treatment last for 4–6 months. Single-dose radiotherapy with a single 
fraction of 7.5 Gy has also been proven to be beneficial in reducing excessive 
drooling (Banfi et al., 2015). 
 
 
2.4.5. Rehabilitation 
Physiotherapy and myogymnastics improve patients with swallowing problems 
due to excess saliva and food. For example, the postural chin-down maneuver is 
effective (Ayres et al., 2017). 
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Behavioral modifying therapy may be an option for controlling sialorrhea 
(van der Burg et al., 2009). 
These methods are most appropriate for neurologically impaired children 
with poor oral skills or hypotonic perioral musculature (Zlotnik et al., 2015). 
Chewing gum may reduce drooling in PD patients (Srivanitchapoom et al., 
2014). 
Oral stimulation plates are effective in neuropediadric patients (Steffen et 
al., 2011). 
 
 
2.5. Oral diseases 
There are two main problems dentists have to deal with: caries and periodontal 
disease. The pathogenesis of these diseases is different. Infection enters the 
organism through the tooth in cases of caries but in periodontal disease 
infection enters the organism through the periodontal tissues. Caries is related to 
low oral pH. In periodontal disease dental calculus formation is caused by high 
oral pH. 
Saliva possesses a buffering capacity for neutralizing acids present in the 
mouth. This can be attributed to several systems such as the phosphate system 
and the carbonic acid or bicarbonate system. Through these systems, saliva can 
maintain its usual pH after a meal. Oral fluid supersaturation with calcium 
phosphates leads to remineralization and maturation of enamel and dentinal 
lesions (Newman et al., 2015). By the same mechanism it may cause calci-
fication of dental plaque resulting in calculus formation on tooth surfaces. 
Calculus is divided into sub- and supragingival and the aetiology of these two is 
different. Supragingival calculus is usually formed at the sites close to salivary 
gland ducts where caries rarely occurs. Exudate from periodontally inflamed 
tissue contains alkaline substances that increase the precipitation of minetal 
salts. This forms subgingival calculus, which is not related to salivary gland 
ducts and may appear around any tooth (Fejerskov et al., 2008). 
 
 
2.5.1. Caries 
Dental caries is also known as a tooth decay. It is a biofilm-dependent infec-
tious oral disease (Ahn et al., 2018). Dental caries is a localized chemical 
dissolution of the tooth surface caused by metabolic events taking place in the 
biofilm (dental plaque) (Newman et al., 2012). Caries is closely related to diet, 
salivation, and the presence of a bacterial biofilm on dental surfaces (Radha et 
al., 2016). 
The most cariogenic bacterium of all oral streptococci in dental biofilms is 
considered to be the S. mutans. The study of Lactobacilli is a new field in oral 
health scientific research. Decrease of plaque pH creates an environment that 
helps the growth of acidophilic microorganisms, such as S. mutans and Lacto-
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bacilli, which promote caries and, with further pH drop, create areas of 
demineralization in the dental enamel. S. mutans is considered a primary cause 
of bacteriological caries. This microorganism plays a major role in the onset and 
progression of dental caries. S. mutans occurs in plaque forming on the surface 
of teeth and produces acids that can dissolve tooth enamel, eventually causing 
cavities. The presence of S. mutans is considered a strong indicator of high 
susceptibility to caries (Fejerskov et al., 2008). The relation of Lactobacilli with 
caries is the opposite. It is considered, that some Lactobacilli species play a role 
in the progression of caries. Its appearance only in saliva and plaque outside of 
carious lesions is not significant. Probiotics can allow beneficial Lactobacilli to 
populate sites on teeth, preventing streptococcal pathogens from taking hold and 
inducing dental decay (Twetman et al., 2008). Lactobacilli presence becomes 
important when it is abundant not only in saliva and plaque but in carious 
lesions too (Jiang et al., 2016). It produces lactic acid, which can corrode teeth 
and cause existing carious lesions to progress, especially in cases of coronal 
caries. Another important factor in the emergence of caries lesions is the 
nutritional conditions. Fermentable carbohydrate intake causes pH fluctuations. 
Shifts in pH changes the chemical composition of biofilm fluid. When the pH in 
the biofilm drops, the dissolution (demineralization) of enamel surface appears. 
On the other hand, when pH goes up, the remineralization process of enamel 
surface redeposition takes place. These processes occur numerous times per 
day. The composition and thickness of the biofilm, salivary secretion rate and 
composition, and the diet and the floride ion concentration in the oral fluids are 
factors that influence the metabolic processes between biofilm and tooth 
surfaces (Fejerskov et al., 2008). 
 
 
2.5.2. Dental calculus as a result of alkaline salivary pH and  
a causative factor for periodontitis 
Dental calculus as a result of alkaline salivary pH is a form of hardened dental 
plaque and is caused by precipitation of minerals from saliva and gingival 
crevicular fluid onto the surface of teeth (Varghese et al., 2015). The rough and 
hardened surface that is formed provides an ideal surface for further plaque 
formation. This leads to calculus buildup, which compromises the health of the 
gingiva. Dental calculus as a result of alkaline salivary pH is divided into 
supragingival and subgingival calculus. The accumulation of dental plaque is 
not only due to the mineralization of non-viable microorganisms but is also a 
complex process supported by enzymes (Doğan et al., 2016). Higher salivary 
calcium content accelerates plaque hardening and thereby indirectly influences 
the level of oral hygiene (Varghese et al., 2015). The calcium concentration of 
submandibular gland-produced saliva is about 45% higher than parotid gland-
produced saliva (Varghese et al., 2015). This is an important factor in oral 
health when choosing target glands for BNT-A injections. Periodontal health is 
disturbed at first by the enzymatic effect of dental plaque bacteria (like alkaline 
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phosphatase, lactate dehydrogenase, and acid phosphatase) and it worsens due 
to the retentive effect of dental calculus formation resulting in periodontal tissue 
inflammation (periodontitis). 
Calculus blocks the effect of oral hygiene procedures and is also a reservoir 
for endotoxins and bacterial antibodies. Calculus formation is influenced by 
age, gender, eating habits, oral care, bacterial composition, host response, 
systemic diseases, and prescribed medications. Not all the plaque becomes 
calcified and some patients with deficient oral hygiene otherwise do not have 
dental calculus and the reason for this situation is still unknown. 
There is some evidence that fetuin-A inhibits apatite formation (Schafer et 
al., 2003). Higher gingival crevicular fluid and saliva fetuin-A levels were 
detected in patients with dental calculus than in patients without dental calculus, 
which may be the result of an adaptive mechanism to inhibit mineral pre-
cipitation and eventually calculus formation (Doğan et al., 2016). Fetuin-A is an 
effective inhibitor protein that is synthesized in the liver and secreted into the 
circulatory system in the case of ectopic calcification. It prevents calcium-
phosphate precipitation in the calcification processes inside the organism, such 
as in the kidneys (Aksoy et al., 2010), coronary arteries (Lehtinen et al., 2007), 
bones (Yang et al., 2007), and brain (Geroldi et al., 2005). 
 
 
2.5.3. Periodontal disease 
Chronic periodontal disease is an inflammatory condition in tooth-supporting 
structures with multifactorial aetiology, caused by anaerobic Gram-negative 
microorganisms. The predominant periodontal pathogens are Aggregatibacter 
actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, 
Fusobacterium nucleatum, Tannerella forsythensis, Eikenella corrodens and 
Treponema denticola (Gurav et al., 2014). Anaerobic species adhere to teeth 
forming bacterial plaque. The target points of inflammation are the gums, 
periodontium and alveolar bone (Puşcu et al., 2016). Numerous studies have 
shown an association between periodontitis and various systemic conditions, 
such as diabetes mellitus, atherosclerosis, cardiovascular diseases rheumatoid 
arthritis, Alzheimer’s disease, chronic nephropathies, dyslipidemia, obesity, etc. 
(Suvan et al., 2011; Newman et al., 2012; Ruospo et al., 2014; Gurav et al., 
2014; Sanchez et al., 2017; Dietrich et al., 2017; Kitagawa et al., 2017; Äyrä-
väinen et al., 2017). Periodontitis is associated with lower intakes of niacin, 
vitamin C, and iron, especially in women and non-smokers (Park et al., 2016). 
Periodontal tissue inflammation is responsible for various cardiovascular 
diseases, including atherosclerosis (Newman et al., 2012). Earlier studies 
showed that systemic illnesses, especially metabolic disorders, affect oral health 
(Löe et al., 1993; Liu et al., 2017), but recent studies prove that the association 
between oral health and systemic health is bidirectional and it appears that oral 
health may affect systemic health likewise (Puşcu et al., 2016). It is hypo-
thesised that Treponema from the oral cavity must have gained access to the 
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cerebral cortex via the trigeminal nerve (Gurav et al., 2014), leading to brain 
infection and damage. A significant association has been demostrated between 
spirochetes and Alzheimer’s disease. Spirochetes were detected in the brain in 
93.7% of Alzheimer’s disease cases and in only 33.3% of the control group. 
Periodontal disease and diabetes mellitus are conditions which usually begin 
after the age of fifty and negatively influence one another. Usually the inflam-
matory reaction in patients with periodontal disease and diabetes is more intense 
than in the patients with periodontal disease without diabetes (Puşcu et al., 
2016). Äyräväinen et al., (2017) reported in their study that nearly 80% of 
rheumatoid arthritis patients suffer under periodontitis versus 40% of the 
control group. Smoking is known to be one of the reasons for exacerbation of 
periodontitis (Roshan et al., 2016). 
 
 
2.6. Prevention of oral diseases 
Maintaining adequate dental and oral hygiene is a challenge especially for 
elderly people and young children due to their limited motor skills (Chand et 
al., 2014; Sjögreen et al., 2015). Patients with PD typically have poor oral 
health (Pradeep et al., 2015) and smoking also increases the morbidity of 
periodontitis (Kitagawa et al., 2017). To combat periodontal disease, PD 
patients need health guidance about tooth brushing and information about the 
importance of quitting smoking and controlling obesity. Oral hygiene in 
disabled patients can be maintained with increased mouth rinsing after meals to 
remove accumulated food from the mouth. Powered toothbrushes, topical 
administration of chlorhexidine, and fluoridated products and calcium phosphate 
are suggested to reduce the risk of caries. (DeBowes et al., 2007; Chibinski et 
al., 2011; Rath et al., 2013). 
Despite the achieved therapeutic effect of the BNT-A treatment, the risk for 
poorer oral condition and decreased self-cleaning ability remains. Caregivers 
and patients should cooperate with dentists to improve oral hygiene and 
maintain good oral health. They need instructions on how to take care of oral 
hygiene, especially in the first month after BNT-A injections when the effect of 
the treatment on sialorrhea is maximal. 
 
 
2.7. Summary of literature review 
Our study was designed to assess the effect and safeness of BNT-injections in 
sialorrhea treatment because there was earlier worldwide effective off-label use 
reports (Brin, 2009; Laskawi, 2008; Majid, 2010), but in Estonia that treatment 
was not implemented previously. BNT-A was not in indication list of Estonian 
State Agency of Medicines for sialorrhea also.  
Earlier studies describe oral health changes only in patients with central 
nervous system diseases due to their bad manual coordination (Pradeep et al., 
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2015) and insufficient brushing, but studies including BNT-A treatment role on 
saliva composition change and through that to dental and periodontal health are 
missing. This study direction is important because BNT-A injections are novel 
approach in sialorrhea treatment and they are always more frequently used 
method. Because of the lack of information, patients receiving BNT-A injections 
have to be under the careful supervision of a dentist or a dental hygienist. 
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3. AIMS OF THE STUDY 
General aim of our study was to evaluate the BNT-A safety and efficacy in 
treatment of sialorrhea in neurologically disabled patients. All three of the 
studies are focused to evaluate the efficiency of the BNT-A treatment. 
1. To elucidate clinical factors that play a role in sialorrhea with CP in Study I. 
2. To evaluate the safety to oral health after the ultrasonography-controlled 
bilateral BNT-A injections into the parotid and submandibular glands in the 
management of sialorrhea in patients with neurodegenerative diseases. Study 
II and III evaluate the risks of BNT-A injections to oral health. 
3. To evaluate and compare salivary compositions and microbiota change after 
BNT-A injections. Study II and III are oriented to evaluate saliva changes 
after the BNT-A injections. 
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4. SUBJECTS AND METHODS 
The study has been approved by the Ethics Review Committee on Human 
Research of the University of Tartu (protocol Nr 192/T-3; 26.04.2010) and the 
State Agency of Medicines (Protocol no. 01-09.02.15). The research has been 
registered to the European Clinical Trials Database (EUDRA 2015-000682-30 
EE 20150417 CTA). Informed consent has been obtained from all study 
participants. 
Study I was an open label, descriptive, non-blinded prospective study in-
vestigating sialorrhea in children. Study II and III were prospective clinical 
trials in the adult population. 
 
 
4.1. Subjects of the studies 
4.1.1. Study I 
Twelve children with CP from the Department of Neurology and Neuro-
rehabilitation of the Children’s Clinic of the Tartu University Hospital were 
admitted to the Study I (The use of Botulinum neurotoxin A in uncontrolled 
salivation in children with cerebral palsy: A Pilot Study). Three participants 
were excluded due to the parents’ refusal to give permission to participate in the 
study, bringing the total number of paediatric patients who completed the study 
down to nine. Patients aged 1.6 to 11 years old (four male and five female) with 
CP, were screened from January 2011 to August 2011. All subjects had 
neurological manifestations of CP: spastic hemiparesis, tetraparesis, or dystonic 
movement disorder. The patients were selected according to the Gross Motor 
Function Classification System (Palisano et al., 1997). This is a five-level 
classification that differentiates children with cerebral palsy based on the child’s 
current gross motor abilities, limitations in gross motor function, and need for 
assistive technology and wheeled mobility. All selected patients had moderate 
to severe intellectual disability. 
 
 
4.1.2. Study II 
Study II (Effect in salivary parameters after BNT-A treatment in sialorrhea 
patients) includes twenty patients, among them twelve males and eight females, 
with an average age of 63.2 years, all exhibiting remarkable hypersalivation. 
The patients were screened from October 2012 to October 2013 at the Tartu 
University Hospital. In 75% of the cases, the aetiology of sialorrhea was caused 
by chronic neurodegenerative diseases. In twelve cases the patients had PD, and 
three patients had ALS. In two cases sialorrhea was caused by birth hypoxia. 
Two patients had atypical headache and one patient had experienced stroke with 
abnormal glutition. 
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4.1.3. Study III 
The participants in Study III (Saliva changes in PD patients after injection of 
Botulinum neurotoxin type A) included patients diagnosed with PD who had 
sialorrhea. Thirty-eight subjects (sixteen female and twenty-two male; age 
range of 58–88 years; mean age of 71.1 years) were screened at the Tartu 
University Hospital from April 2015 to January 2016 and enrolled in the study. 
The participants were selected from the cohort of patients included in the PD 
epidemiology study at the Department of Neurology and Neurosurgery of Tartu 
University. The healthy control group was recruited from the department of 
Dentistry. The patient assessment was based on screening by the Movement 
Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) 
questionnaire, Item 2.2 from Part II (Non-Motor Aspects of Experiences of 
Daily Living) (Goetz et al., 2008). All participants were divided into three 
groups: Group 1 of twelve PD patients (nine male and three female, with an 
average age of 71.3 years) with sialorrhea, was treated with salivary gland 
BNT-A injections. Group 2 included thirteen PD patients without hyper-
salivation (seven male and six female, average age 71.5 years) who did not 
receive BNT-A injections. Group 3 comprised thirteen age- and sex-matched 
healthy volunteers (six male and seven female, average age 70.6 years). 
 
 
4.2. Methods 
Intervention with BNT-A injection procedures was performed in all three 
studies. In Studies II and III, salivary analysis was performed alongside the 
BNT-A procedure. For the control group, salivary tests were performed without 
BNT-A injections. 
 
 
4.2.1. BNT-A injection techniques 
The study groups received BNT-A injections into the salivary glands. The solu-
tion of 100 U of BNT-A (Botox®) was prepared in a 2.5 mL volume of saline 
solution. The dose was calculated according to body weight. The recommended 
dose for Botox® (Allergan) was weight-dependent: 1.4 U per kg of body weight 
for injection to each parotid gland, and 0.6 U per kg in each submandibular 
gland (total dose of 2 U per kg) (Reddihough et al., 2010). The recommended 
Botox® dose was tripled to get the relevant dose of Dysport® (Reddihough et 
al., 2010). In the children of Study I, BNT-A injections were done under 
general anesthesia. The injection procedures were done under local anesthesia 
for adult patients in Study II and III. Ultrasound guidance was used in all cases 
of BNT-A injections. The 7.5 mHz linear transducer was positioned so that it 
was possible to perform an injection with a needle directed along the 
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longitudinal axis of the transducer. 27-gauge needles were placed in the antero-
posterior direction into each submandibular and parotid gland. 
 
 
4.2.2. Assessing BNT-A treatment effectiveness 
To determine children’s responses to the treatment in Study I, a structured tele-
phone interview with one parent or caregiver was used. The interview schedule 
for Study I was designed based on the literature review and past experience. 
Drooling severity at baseline and reduction of sialorrhea during treatment were 
assessed using a parent’s questionnaire containing previously known scales. 
Drooling intensity and frequency were evaluated with the Drooling Severity and 
Frequency Scale (Table 1) (Thomas-Stonell et al., 1988) and Teacher Drooling 
Scale (a 5-point scale: 1- no drooling, 2- infrequent drooling, small amount  
3- occasional drooling, on and off all day, 4- frequent drooling, but not 
profusely 5- constant drooling, always wet) (Reid et al., 2010). The baseline 
rate of salivation was assessed before the BNT-A injection. After BNT-A 
treatment the rates of salivations were assigned with biweekly evaluations over 
a six-month span with self-assessed rating scales for drooling intensity, 
discomfort, and treatment efficacy (Benson et al., 2007). The patient interview 
included an evaluation of their medical and psychological history, and a 
consideration of their sialorrhea aetiology. Reporting on drool reduction, bib 
changes, need for suctioning, respiratory distress, self estimated quality of life, 
and complications such as facial swelling and swallowing dysfunction was 
included in the interview. Treatment efficacy and safety were assessed at base-
line, and in a one-month follow-up after the BNT-A injections. Side effect 
prevalence was also measured (Mancini et al., 2003). 
Participants of Study II and III were evaluated by questionnaire twice, before 
injections, and one month after the BNT-A treatment, to investigate the effect 
and changes in self estimated quality of life. Teacher Drooling Scale and  
MDS-UPDRS Item 2.2 from Part II (Non-Motor Aspects of Experiences of Daily 
Living) and was used in Study II and III (Reid et al., 2010; Goetz et al., 2008). 
 
Table 1. Drooling Severity and Frequency Scale 
Drooling severity scale 
1=Never drools, dry 
2=Mild – drooling, only lops wet 
3=Moderate – drool reaches the lips and chin 
4=Severe – drool drips off chin and onto clothing 
5=Profuse – drooling off the body and onto objects (furniture, books) 
 
Drooling Frequency Scale 
1=No drooling 
2=Occasionally drools 
3=Frequently drools 
4=Constant drooling 
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4.2.3. Salivary tests 
Salivary tests were used in the subjects of Study II and III. In Study III (Group 1), 
patients took salivary tests before the injections and one month afterwards and 
control group subjects (Group 2 and 3) took salivary tests once. Throughout the 
study, medications known to influence the severity of drooling were not used. 
The patients, their caregivers, and their families were made aware of the 
possible adverse effects and risks related to the study interventions. 
The Saliva-Check BUFFER in Vitro test (GC EUROPE N.V. B-3001 Leuven, 
Belgium) was used to determine the quality, pH, and buffering capacity of 
saliva. 
In order to test resting saliva, three different tests were used: 
1. Resting saliva formation was tested by visual inspectation of level of hyd-
ration. The lower lip has to be everted and labial mucosa gently blotted with 
a small piece of gauze. Then, under good light, observe how quickly the 
droplets of saliva express from the minor glands (in seconds). 
2. Saliva consistency was also assessed by visual evaluation. Saliva was 
characterised as (1) sticky-frothy, (2) frothy-bubbly, or (3) watery-clear. 
Watery-clear saliva is referred as of normal viscosity. Sticky-frothy and 
frothy-bubbly saliva is characterised by increased viscosity. 
3. For pH measurement, subjects had to expectorate pooled saliva into the 
collection cup. pH test strips were held in samples for ten seconds and 
compared with the chart in the kit. 
 
In order to test stimulated saliva, two different tests were used: 
1. The amount of saliva was determined by the quantity of saliva secretion over 
the course of five minutes. Subjects had to chew a piece of wax to stimulate 
salivary flow. Every thirty seconds patients had to expectorate the 
accumulated saliva into the marked collection cup. The amount was checked 
with the ml markings on the side of the cup. It is noted that a normally 
stimulated flow rate varies between 1 ml/min–1.6 ml/min. 
2. To assess buffering capacity, Buffer test strips were used. The strips were 
placed onto absorbent tissue and the saliva drop was then dispensed onto 
each of the three test pads with the pipette. Excess saliva was soaked up with 
absorbent tissue. After two minutes the test pads changed their colour and 
the final result was calculated from 0 to 4 points, according to the final 
colour of each pad. The combined total scores were described as follows:  
0–5 points show very low buffering ability of saliva; 6–9 points show a low 
buffering ability; and 10–12 points show normal or high buffering ability. 
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4.2.4. Analysis of salivary cariogenic bacteria 
Salivary levels of the cariogenic bacteria S. mutans were measured using 
Dentocult SM, and Lactobacilli were measured by using Dentocult LB (Orion 
Diagnostica Co Ltd, Epsom, Finland). To detect S. mutans in a saliva sample, 
Dentocult SM Strip mutans was applied. The method was based on the 
adherence and growth of S. mutans on the test strip (Thorhild et al., 2002). 
S. mutans bacteria adhere to the rough area of the strip in proportion to their 
density in saliva. After incubation, the bacteria are visible as light to dark blue. 
Dentocult LB is a dipslide culture method for detecting aerobic aciduric bacteria 
(i.e. Lactobacilli) in stimulated saliva. Aciduric bacteria are seen as white to 
transparent colonies on modified Rogosa agar surface. Bacterial growth may 
consist of both large and small colonies. Colony density should be compared to 
a reference, using a model chart, irrespective of colony size. 
To avoid the effects of daily variation in Lactobacilli counts on the treatment 
result, it is recommended to take samples before noon. If this recommendation 
cannot be followed, samples from the same patient should be taken at the same 
time of the day during follow-up sampling (Birkhed et al., 1981). Prior to 
sampling, the patients did not eat, drink, smoke, or brush their teeth for two 
hours. The incubation periods for Dentocult LB and Dentocult SM were 96 and 
48 hours, respectively (Schlagenhauf et al., 1995). Dentocult LB sample was 
placed in the incubator (36 ± 2°C) for four days, and Dentocult SM sample, for 
two days. To assess colony count (CFU/ml), the slide was removed from the 
tube and colony density on agar surface was compared to the reference chart 
provided in the kit (Birkhed et al., 1981). 
 
 
4.3. Statistical analysis 
The data was analysed using IBM SPSS Statistics V20 (IBM Corporation, 
Armonk, NY, USA). All three studies used descriptive analytical methods: the 
calculation of means, standard deviations (SDs), and median values were used 
for continous variables, depending on the distribution. Differences between the 
study groups in Study II were compared with the Paired Samples t-test, Wil-
coxon Matched Pairs Signed Ranks Test, and Ficher’s Exact Test. Differences 
between the study groups in Study III were compared with Kruskal-Wallis or 
ANOVA test. The data without normal distribution was analysed with the 
Wilcoxon Signed Ranks test. Pearson’s correlation was used to analyse 
relationships between the different parameters in Study III. 
The two-sample t-test, the two-proportion z-test, and the Mann–Whitney test 
were used to assess the differences of the variables of interest between the two 
independent groups. The Wilcoxon signed-rank test was used to analize non-
parametric data, and paired t-test for parametric data analysis. Pearson’s 
correlation analysis was used to evaluate the associations between variables. 
Differences with p values < 0.05 were considered statistically significant. 
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5. RESULTS 
5.1. Use of Botulinum neurotoxin A in uncontrolled 
salivation in children with cerebral palsy (Study I) 
The results of the first part of our study (Study I) showed an increased fre-
quency of malocclusion (mostly open bite) and insufficient lip closure in 
children with CP that occurs due to weak head and neck musculature and 
dysphagia, which causes breathing through the mouth while at rest, instead of 
normal breathing through the nasal cavity. When the mouth is held open, saliva 
spills out. Anterior drooling was found in five cases, and posterior drooling in 
three cases out of nine; one patient had both types of drooling. All patients had 
oral spasticity, with slow uncoordinated tongue movements noted in eight 
patients. The clinical characteristics of patients are shown in Table 2. 
Children with sialorrhea had a maximum response to the BNT-A injection 
between two weeks and two months post-injection. A direct decrease in 
drooling according to the Drooling Severity and Frequency Scale was reported 
at the first week, subjectively. The number of bibs used per day (Figure 1) and 
the need for suctioning (Figure 2) also dropped by almost half. About two 
weeks after the BNT-A injection, patients’ saliva flow decreased for the liquid 
component. Saliva thickened. Drooling decreased from a score of 5 (profuse) at 
baseline to 3 (moderate) by two weeks after treatment (Figure 1). 
One child out of nine had no response to the BNT-A injection, and one child 
had difficulties swallowing for three weeks as a complication of BNT. There 
were no complaints of pain or swelling in the research group. 
The main effect on self estimated quality of life was seen in the first two 
months but later decreased. Three caregivers reported a remarkable increase in 
quality of life, another three described a good increase, two reported a moderate 
increase, and one did not see any change in quality of life (Figure 3). 
Parents of CP patients preferred to undergo this treatment option in winter 
during the season of respiratory infections, which may cause saliva-soaked 
clothes.  
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Figure 1. The number of bibs used per day  
Figure 2. Need for saliva aspiration in time 
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Figure 3. Patients self estimated quality of life 
 
 
5.2. Effect in salivary parameters after BNT- A treatment  
in sialorrhea patients (Study II) 
Treatment efficacy and safety were assessed in twenty patients with profuse 
sialorrhea (twelve male and eight female) at baseline, and at a follow-up after 
the BNT-A injections, using Item 2.2 from Part II, MDS-UPDRS (Goetz et al., 
2008) and salivary tests. The average age of participants was 63.15 years 
(ranging from 3 to 79 years). The aetiology of sialorrhea was caused by chronic 
neurodegenerative diseases in 75% of the cases, and by other reasons in 15% of 
the cases. In twelve cases the patients had PD; in three cases ALS was 
diagnosed; in two cases birth hypoxia was a cause of sialorrhea; two patients 
complained atypical headache; and one patient had experienced stroke with 
dysphagia. 
Subjective severity was recorded according to the MDS-UPDRS scale Item 
2.2 at baseline and one month after the injection procedure. Of all the study 
patients, 95% reported a significant decrease in drooling one month after the 
injections. A statistically significant decrease in the amount of saliva was found 
according to the Teacher Drooling Scale, dropping from the severe/moderate 
level to mild. The amount of stimulated saliva decreased, and the duration of  
at-rest saliva formation increased significantly. Buffering capacity went up, 
which showed that salivary defence ability had improved. Oral pH had no 
significant changes. In the follow-up visit, there was no statistically significant 
change in oral pH and buffering capacity compared to the initial assessment. 
The results are shown in Table 3 
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Like the results of the first study, all patients in Study II had saliva thic-
kening for two months after the BNT-A injections. Saliva consistency changed 
significantly according to Ficher’s exact test (p = 0.004). Before the BNT-A 
injections, watery-clear saliva was the most common consistency (90% of the 
patients), and none had sticky-frothy saliva. After the injections, the most 
common consistency by the visual assessment was frothy-bubbly saliva (65% of 
the patients), and sticky-frothy saliva occurred in one case. 
A comparison of different Lactobacilli and S. mutans colony forming unit 
(CFU) count groups before and one month after the BNT-A injections demon-
strated a tendency for increased microbial levels, but the change was not 
statistically significant (Table 3). 
All participants tolerated the treatment well. There were no complaints of 
swelling or pain in the study group. 
 
Table 3. Comparison of salivary characteristics before and one month after the injec-
tions 
Characteristic Before 
injections (SD)
1 month after 
injections (SD) 
p 
Subjective evaluation of salivation 
(MDS-UPDRS Item 2.2 score) 
3.7 (± 0.6) 2.0 (±1.2) 0.001* 
Resting saliva time (sec) 20.7 (±15.1) 34.3 (±19.7) 0.002* 
Stimulated saliva amount (ml) 7.1 (±5.6) 4.5 (±3.4) 0.006* 
Oral pH 6.7 (±0.7) 6.8 (±0.7) 0.494 
Buffering capacity (points) 6.5 (±3.2) 8.2 (±3.1) 0.082 
Lactobacilli (CFU/ml) 0.9 × 106 3.1 × 106 0.052 
S. mutans (CFU/ml) 105–106 105–106 0.707 
p* statistically significant 
Wilcoxon Signed Ranks Test, n=20 
 
 
5.3. Saliva changes in Parkinson’s disease patients after 
BNT-A injections (Study III) 
This research was performed on elderly individuals with PD. Differences in 
salivary tests were compared across three groups: Group 1 consisted of twelve 
PD patients (nine male and three female) who suffered from drooling and 
received BNT-A injections in their salivary glands, Group 2 consisted of 
thirteen PD patients without excess saliva (seven male and six female) who 
were not injected with BNT-A, and Group 3 consisted of thirteen age-matched 
healthy controls (six male and seven female). The characteristics of the study 
PD participants according to the groups are described in Table 4 An association 
was found between long-term levodopa use and drooling (Pearson’s correlation, 
p=0.034). Group 1, which received BNT-A treatment for drooling, had a 
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significantly longer levodopa treatment duration. The amount of saliva was 
greater in patients who were treated with levodopa (Pearson’s correlation,  
p = 0.016) and less in patients on MAO-B inhibitors (Pearson’s correlation,  
p = 0.020). 
 
Table 4. Characteristics of the study participants according to the group. 
Characteristic Group 1 (n=12) Group 2 (n=13) p-value 
PD onset age, yr (mean ± SD) 57.7 ± 9.6 63.7 ± 8.1 0.102 
PD duration, yr (mean ± SD) 13.4 ± 6.6 7.8 ± 4.6 0.019* 
Clinical subtype of PD, n (%) 
Tremor-dominant 1 (8%) 9 (69%) 0.0018* 
Akinetic-rigid 8 (67%) 4 (31%) 0.005* 
PIGD 3 (25%) 0 (0%) 0.055 
HY, median (ranges) 3 (2–4) 2.5 (1.5–3) 0.005* 
MDS-UPDRS part II (mean ± SD) 17.7 ± 7.7 9.9 ± 4.1 0.004* 
Item 2.2. Saliva and drooling (mean ± 
SD) 
2.9 ± 1.1 0.2 ± 0.4 <0.001* 
MDS-UPDRS part III (mean ± SD) 50.1 ± 19.8 27.2 ± 9.6 0.001* 
Antiparkinsonian treatment, n (%) 
Amantadine 7 (58%) 3 (23%) 0.074 
MAO-B inhibitors 3 (25%) 3 (23%) 0.907 
Dopamine agonists 7 (58%) 8 (62%) 0.838 
Levodopa 11 (92%) 9 (69%) 0.151 
LEDD, mg (mean ± SD) 1024.8 ± 576.5 405.4 ± 288.3 0.002* 
Levodopa daily dose, mg (mean ± SD) 568.2 ± 234.8 355.6 ± 142.4 0.029* 
Duration of levodopa treatment, yr 
(mean ± SD) 
9.2 ± 5.2 4.5 ± 3.7 0.034* 
Mann-Whitney U test for statistical significance 
a number (proportion) of patients; two proportion z-test for statistical significance 
* Statistically significant  
Abbrevations: PD= Parkinson’s disease; SD = standard deviation; yr = years; PIGD = 
postural instability and gait disorder; HY = Hoehn and Yahr stage; MDS-UPDRS = 
Movement Disorders Society Unified Parkinson’s Disease Rating Scale; LEDD = 
levodopa equivalent daily dose. 
 
Resting time saliva formation shows how quickly a drop of saliva appears from 
the minor salivary glands of the lower lip. It was slower in patients with later 
disease onset of PD. 
An association was found between the initial amount of 5-minute saliva and 
the leading symptom (Pearson’s correlation, p = 0.016). The patients with 
akinesia-rigidity as a leading clinical syndrome had more sialorrhea than 
patients with tremor-dominant PD (Pearson’s correlation, p = 0.0019). 
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All patients in Group 1 reported thickening of saliva for one month after 
BNT-A injections. Subjective assessment by the MDS-UPDRS Item 2.2 
demonstrated the change in drooling from very intensive at the baseline, to the 
moderate level (mean 3.55, SD 0.688, median = 4.00) and one month after the 
BNT-A injections (mean 1.55, SD 1.214, median = 1.00) (p = 0.01), and the 
amount of saliva collected in the 5-minute test showed a significant decrease 
(Table 5). The consistency of saliva and the pH values did not change after the 
injections. The higher buffering capacity values after the injection demonstrated 
the ability of saliva to maintain a normal oral pH (Table 5). There were no 
significant changes in the count of S. mutans, but the Lactobacilli counts were 
statistically significantly increased (Table 5). 
The treatment was generally well-tolerated and there were no complaints of 
swelling or pain by the patients. 
 
Table 5. Change in saliva parameters across Groups. 
Saliva parameters Group 1 Group 2 Group 3 
Before 
BNT-A 
injection 
1 month after
BNT-A 
injection 
p 
Resting saliva formation 
time (sec) (range) 
15 (5–60) 25 (16–75) 0.05* 20 (7–78) 26 (10–60) 
Amount of 5 min 
collected saliva (ml± SD) 
8.6 ± 6.79 4.8 ± 4.09 0.018* 6.0±3.5 6,3±4.0 
Buffering capacity 
(range) 
5 (2–12) 9 (3–12) 0.037* 9 (3–12) 8 (2–12) 
Consistency (range) 3 (2–3) 2.5 (2–3) 0.059 3 (3) 3 (2–3) 
pH (±SD) 7.0 ± 0.74 7.0 ± 0.95 1.00 7.3±0.86 7.2±0.8 
Dentocult LB counts 
(Lactobacilli) (range) 
1 (0–3) 2 (0–3) 0.047* 2 (0–3) 1 (0–2) 
Dentocult SM counts 
(S.mutans) (range) 
2 (0–3) 2 (2–3) 0.206 2 (0–3) 2 (0–3) 
p* statistically significant 
Abbrevations: BNT-A, Botulinum neurotoxin type A 
Median ± SD (range) 
Wilcoxon Signed Ranks Test, n=38 
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6. DISCUSSION 
6.1. Sialorrhea etiology 
Excessive drooling can be a serious physical and social disability, affecting 
communication, and greatly reducing quality of life. In neurological disorders 
(CP, PD, ALS) usually the main problem with saliva excess is related to 
dysfunctional oral motor control when the swallowing process is abnormal due 
to muscle weakness (Hussein et al., 1998; van Hulst et al., 2018). 
Clinical factors like head position, lip seal, voluntary control of tongue 
movements, and mental stage, influence drooling (Dias et al., 2016), which is in 
concordance with the results of our study. Tongue mobility is associated with 
drooling control. The results of the first part of our study (Study I) showed an 
increased malocclusion in children with CP sialorrhea that is explained with 
weak head and neck musculature and disturbed swallowing. While at rest, nasal 
breathing is changed to mouth breathing. When the mouth is held open, saliva 
spills out. 
The results of Study III showed remarkable sialorrhoea in PD patients with a 
prominent clinical syndrome of akinesia and rigidity than in patients with 
tremor as a leading symptom, which demonstrates a connection between a 
clinical subtype of the disease and swallowing dysfunction. Another study has 
shown an association between hypokinesia and rigidity and swallowing 
function, which may be worsened by malnutrition with decreased liquid intake 
and eating soft sticky food (Müller et al., 2011). 
Furthermore, PD medications, including levodopa, dopamine agonists, 
MAO-B inhibitors, amantadine, and anticolinergics may have oral implications 
like xerostomia, bruxism, dry throat, gingivitis, tongue edema, abnormal taste, 
and glossitis (DeBowes et al., 2013; Zlotnik et al., 2015). Our study showed an 
association between long-term levodopa use and drooling. Sialorrhea was more 
prevalent in patients who were treated with levodopa and less so in patients 
treated with MAO-B inhibitiors. Most PD medications including levodopa are 
responsible for xerostomia emergence in the early stage of PD. Levodopa might 
stimulate the salivary flow rate and lead to an excessive amount of saliva in a 
later stage of PD (DeBowes et al., 2013). This could also be explained by the 
fact that levodopa’s effect decreases with time: after 5–10 years of treatment, at 
least half of the patients become partially unresponsive to the medication 
(Giladi et al., 2016). 
 
 
6.2. Sialorrhea treatment effects with BNT-A 
Intraglandular application of BNT-A guided by a high-resolution ultrasound can 
provide reliable treatment of sialorrhea with a favourable outcome (Wilken et 
al., 2008; Sriskandan et al., 2010; Petracca et al., 2015). Our results are in line 
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with previous studies showing that BNT-A reduces drooling effectively (Ou et 
al., 2015; Gómez-Caravaca et al., 2015). 
Lee et al. (2010) recommend blind injections with BNT-A based on 
anatomical landmarks, but we chose to use ultrasonic guidance for safety 
reasons. The parotid glands are easy to locate blindly, but there is a higher 
failure rate when injecting the submandibular glands blindly due to their more 
difficult detection (So et al., 2017). 
There are different options for the technique used to administer BNT-A into 
the parotid gland regarding the number of injection points (Manrique et al., 
2005). We used the single-point technique to target glands. Many authors, 
including us, prefer to inject both the parotid and submandibular glands but 
some authors consider this less effective than submandibular injections alone. 
Scheffer et al. (2010) prefer the submandibular glands as these are responsible 
for 60% to 70% of unstimulated saliva production, but the parotids mainly 
secrete saliva during mastication. In some studies, injections were performed 
solely into the submandibular glands, to avoid reduction in parotid output at the 
time of eating and drinking (Jongerius et al., 2004). On the contrary, Gómez-
Caravaca et al. (2015) showed a favourable result in 65% of cases, injecting 
only the parotid glands blindly, which are accessible due to their superficial 
location and make a large contribution to total saliva output (Fuster-Torres et 
al., 2007). Suskind et al. (2002) showed a favorable outcome in 30% of patients 
when injecting only their submandibular gland, and 80% in patients injected in 
both their submandibular and parotid glands. The first part of our study (Study 
I) showed that the BNT-A injection into both the submandibular and parotid 
glands was effective in 89% of cases using that technique. We selected both 
bilateral parotid and submandibular glands as the treatment targets to optimize 
the therapeutic outcome of BNT-A intrasalivary gland injections. 
The wide range of dosages of BNT used for treatment of hypersalivation is 
related to the diagnosis of the patient, the severity of the sialorrhea, the injection 
technique, and the experience of the physician (Laskawi et al., 2008). Several 
studies have shown that the effect of BNT is dosage-related: the higher the dose 
of BNT-A, the higher the efficacy of injections (Restivo et al., 2018). Patients 
in our study received a weight-dependent dosage total of 6 U/kg abobotulini 
(Dysport). As the total dosage of BNT-A was calculated according to 
bodyweight, the cause of unresponsiveness in one child might be related to an 
insufficient dose. 
The return of hypersalivation four to seven months after BNT-A treatment 
was noted in 21% of patients who requested a second injection (Ellies et al., 
2004). Salivary flow rates in our CP study dropped remarkably within one week 
after the injections but increased again after twelve weeks. Our results showed 
that high salivation rates returned after three to four months. The duration of the 
toxin’s effect varies widely among individuals. Generally, the effect of 50 to 65 
U of BNT-A (Botox®; Allergan, Irvine, CA) in both the submandibular and 
parotid glands under sonography application lasted for about three months 
(Ellies et al., 2004). We speculate that the reason for the wide range in the 
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duration of BNT-A’s effect could be related to differences in total dosages 
between studies. Moreover, the injection technique might have an impact on the 
duration of effect, as overly superficial injections might lead to some extra-
glandular absorption. 
Earliest study showed the appearance of many complications such as 
dysphagia, xerostomia, and chewing difficulties (Alvarenga et al., 2017), but 
there is a study describing no side effects of BNT-A treatment (Mahadevan et 
al., 2017). In our CP study group, one patient had swallowing difficulties for 
three weeks, and six patients had extensive thickening of saliva lasting eight 
weeks. Thickened saliva after the BNT-A injections affects the mouth’s natural 
self-cleaning ability as the thick saliva cannot wash the dental plaque off teeth. 
El-kwatehy et al. (2016) showed that salivary flow rate does not correlate with 
dental caries. 
BNT-A injections into salivary glands do not need general anesthesia but 
can be performed under intravenous sedation (Çiftçi et al., 2013). We used 
general anesthesia for children with infantile CP sialorrhea (Study I and II). 
Injections for adult patients were done with local anesthesia without any 
problems (Study II and III). Some parents of children in Study I did not want 
reinjections because of short duration of its effect and the need for general 
anesthesia. Crysdale et al. (2006) and Scheffer et al. (2010) compared surgical 
treatment with BNT injections in children with sialorrhea, and found that both 
interventions were effective, but surgery had a larger and longer-lasting effect. 
In their protocol, the surgical treatment included submandibular duct relocation 
to the posterior area with sublingual gland removal, which was noted as un-
suitable for children with a high risk of aspiration (posterior drooling). Removal 
of the submandibular gland may reduce the salivary flow by more than 80% 
(Hernández-Palestina et al., 2016) and is suggested to CP patients who do not 
respond to BNT-A treatment. Out of nine CP children, only one was non-
responsive. 
 
 
6.3. Salivary parameters as a risk factor for caries and 
periodontitis 
BNT-A injections decrease the amount of saliva and may lead to changes in the 
oral environment and health. Study II demonstrated an effective control of 
sialorrhea with BNT-A without compromising saliva’s protective effect on the 
oral environment. Earlier studies showed that BNT-A can effectively treat 
sialorrhea but its effect on saliva characteristics, including the amount of 
cariogenic bacteria, was unclear (Pei-Hsuan et al., 2011). 
It has been proven that children with different disabilities had more prob-
lems with oral health than the healthy control group (Gaçe et al., 2014; 
Bartolomé-Villar et al., 2016). Children with intellectual disablity have less 
plaque and a lower salivary pH (Radha al., 2016). Proper mastication is an 
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important factor in oral health (Sanjay et al., 2014). Several studies have 
reported that children with various disabilities have higher levels of untreated 
caries and periodontal disease than children without disabilities (Gace et al., 
2014; Lewis et al., 2009). A higher incidence of periodontal disease is asso-
ciated with a lack of manual dexterity (Radha et al., 2016). Our study showed a 
statistically significant decrease in the amount of stimulated saliva collected 
during the 5-minute test, mostly produced by the parotid glands. A decrease of 
this parameter may be explained by our injection scheme with higher doses in 
the parotid glands. 
Our study showed statistically significant retardation in at-rest saliva for-
mation, which is measured from the lower lip’s minor glands. This decrease is 
an unexpected finding with injections of BNT-A only into the major glands. We 
speculate, that could be related to the systemic effect of BNT-A injection and 
not only to the local effect. 
Saliva amount, flow rate, pH, and buffering capacity are significant aspects 
of oral health (Gopinath et al., 2006). Salivary flow pH and buffering capacity 
are factors that influence the risk of dental caries (Liu et al., 2014). Low 
salivary flow (resting time saliva formation < 60 sec. and amount of saliva col-
lected in 5 min. < 3.5 mL), highly acidic pH (5.0–5.8), and lower values of 
buffering capacity (0–5) increase the risk of caries. 
Buffering capacity and pH can impact oral health directly. Buffering is 
saliva’s capability to respond to changes and to correct them in the oral cavity. 
Low buffering capacity is associated with caries development through its 
impaired neutralization of plaque acids and reduced remineralization of early 
enamel lesions (El-kwatehy et al., 2016). Salivary pH can be referred to as an 
indicator for assessment of caries risk and general oral health. Caries-active 
individuals who have a higher risk for caries show larger quantities and faster 
rates of acid production compared to caries-free individuals. Salivary pH was 
significantly lower in caries-affected children than in caries-free children  
(El-kwatehy et al., 2016). The results of Study II and III showed no statistically 
significant change in pH before and one month after BNT-A injection showing 
that pH change is not a risk factor for caries in sialorrhea treatment. In Study II 
buffering capacity had no statistically significant change but in Study III 
statistical significance was found in oral environment improvement after BNT-
A treatment. This could be related to main diagnosis of participants. Study II 
consist of patients with different genesis of sialorrhea (CP, ALS and PD) but 
Study III involved only PD patients. ALS patients often complain about sticky 
secretions but this is not only due to salivary glands but may also originate from 
the nasal and oral mucous glands (Jackson et al., 2015). Sticky secretions as a 
result of a BNT-A injections may be an issue for patients with ALS too. That 
could be a reason for the worsening of dysphagia and the refusal of reinjections. 
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6.4. Salivary S.mutans and Lactobacilli counts  
after BNT-A treatment 
Individuals with intellectual disabilities tend to have inferior oral hygiene and 
higher rates of dental diseases, including caries and periodontitis, in comparison 
with the general population. Changes in the oral environment’s microbial 
ecosystems increase the potential for pathogenicity within a microbial eco-
system and subsequently initiate and promote oral diseases (Baliga et al., 2013). 
Individuals with intellectual disabilities have a significantly higher proportion 
of S. mutans and S. sobrinus among their oral bacteria and have a higher risk of 
dental caries (Oda et al., 2016). No significant difference was found in the 
microbiome diversity in caries-affected children compared to caries-free children, 
while the level of Rothia dentocariosa, Actinomyces graevenitzii, Veillonella sp. 
oral taxon 780, Prevotella salivae, Lactobacillus Scardovia and S. mutans was 
higher in the caries-affected group (Jiang et al., 2016). Lactobacilli and Strepto-
coccus mutans are the two main cariogenic microorganisms affecting oral 
health and caries formation (Petersson et al., 2002). Because of that, we focused 
on these microbes in our study. The concentration of salivary Lactobacilli 
represents a risk factor of caries (Pienihäkkinen et al., 1995; Peterssen et al., 
2002; Kutsch, V.K., 2014). Colony counts of > 10,000 CFU/ml are considered 
high, and counts of < 1,000 CFU/ml are considered low, according to literature 
data (Crossner et al., 1977). Carbohydrate intake has been shown to correlate 
with salivary Lactobacilli counts in the mouth (Gabre et al., 1999). In our study 
the patients with PD tended to have increased Lactobacilli counts of > 105 
CFU/ml, showing higher caries active oral environment, compared to healthy 
controls, who had counts of < 105 CFU/ml showing lower caries active oral 
environment, though the difference was not statistically significant. However, 
the presence of high numbers of Lactobacilli (105 CFU/ml or higher) indicates a 
caries-inducing oral environment. 
S. mutans counts in our study did not differ statistically significantly before 
sialorrhea treatment between PD patients and healthy controls, being in the 
range of 105–106. Still, we should consider that the controls were elderly as age-
matched to the PD group, and also that they might have a more caries-active 
oral environment. 
High Lactobacilli counts are related to low salivary secretion rate, low 
salivary buffering capacity, and the presence of glucose in saliva (Larmas, 
1992). Our second study of sialorrhea patients with different neurological diag-
noses (Study II) did not find statistically significant changes in salivary 
Lactobacilli and S. mutans counts after BNT-A treatment though there was a 
tendency for there to be increased Lactobacilli counts, but in our third study on 
PD patients (Study III) we found an increase in Lactobacilli counts after BNT-
A treatment, which is important to note as a risk factor for caries (Pienihäkkinen 
et al., 1995). Our results in Study II showed that the salivary flow rate 
decreased while salivary pH and the levels of S. mutans and Lactobacilli did not 
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change significantly after the injections. We had a favorable decrease in the 
salivary flow rate, which still might be related to the development of caries. 
Lactobacilli is considered to play a role in caries formation but in cases of 
periodontal disease it could produce the opposite effect. The rise in our study’s 
Lactobacilli counts does not mean an absolute worsening of the oral environ-
ment. Innovative researches have expressed a hypothesis on the possible 
beneficial effects of some Lactobacilli on oral health (Kutsch 2014; Ahn et al., 
2018). Lactobacillus acidophilus culture relieves gingivitis and periodontitis. 
Some Lactobacillus strains can inhibit biofilm formation of oral pathogenic 
bacteria (Ahn et al., 2018). They produce antimicrobial molecules, improve the 
epithelial barrier function, and inhibit the adherence of pathogens to epithelial 
cells (Ahn et al., 2018). Lactobacillus plantarum, Lactobacillus reuteri, and 
Lactobacillus rhamnosus GG inhibit S. mutans biofilm formation (Ahn et al., 
2018). There is also a study showing that oral administration of Lactobacilli 
changes the bacterial population in subgingival plaque in chronic generalized 
periodontitis in a positive way (Imran et al., 2015; Kõll et al., 2007). Probiotic 
drink intake containing Lactobacillus casei leads to a significant reduction in 
the three main pathogenic bacteria of periodontitis (Porphyromonas gingivalis, 
Aggregatibacter actinomycetemcomitans, Prevotella intermedia) and has a 
beneficial effect on periodontal conditions (Imran et al., 2015). Probiotics like 
lactobacilli are considered to be useful in reducing gingival inflammation as 
well as levels of pathogenic microorganisms in the saliva and subgingival 
plaque. They are nonpathogenic bacteria that change or replace the intestinal 
microbiota and have a beneficial effect on the host (Imran et al., 2015). There is 
some evidence that products containing probiotic Lactobacilli also reduce the 
recurrence of apthous ulcers, decrease caries risk, and the number of Strepto-
coccus mutans in the oral cavity (Imran et al., 2015). The results of Study III 
demonstrated a statistically significant increase in Lactobacilli counts but still 
does not clarify its negative or positive consequences on oral health as the 
strains of Lactobacilli were not specified. 
 
 
6.5. Treatment of sialorrhoea with BNT-A in Parkinson’s 
disease patients patients 
Study III focused on the oral condition of PD patients who had been described 
as disturbed compared to controls due to their resting tremor, bradykinesia, 
akinesia, and limited mobility (Bakke et al., 2011; Müller et al., 2011); these 
patients have more caries, dental plaque and food derbis, and missing teeth. 
Orofacial dysfunction with lower mastication and jaw opening lead to dysphagia 
and food retention in PD patients. However, Fukayo et al. (2003) did not find 
poorer oral health in PD patients than in the control group. Drooling is more 
likely associated with oropharyngeal bradykinesia, hypomimia, dysphagia, and 
more severe involuntary mouth opening in PD (Kalf et al., 2012; Karakoc et al., 
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2016). Several studies have reported that patients with PD have lower salivary 
flow, but increased excretion velocity to stimulus compared to healthy controls 
(Tumilasci et al., 2006; Nicaretta et al., 2008; Fedorova et al., 2015). Our 
results showed that salivary parameters (resting saliva formation, consistency, 
amount of saliva collected in the span of 5 minutes, pH, and buffering capacity) 
did not differ before BNT-A injections between PD patients and controls 
showing that our patients have sialorrhea due to impaired swallowing ability 
and not overproduction of saliva, as other studies have shown. 
Xerostomia is an early manifestation of PD due to significantly lower saliva 
production than in the control group (Proulx et al., 2005). Droolers are usually 
older, have a more severe stage of PD, and have a longer disease duration 
(Zlotnik et al., 2015). Problems with drooling can be a result of levodopa treat-
ment (Llena-Puy, 2006; Tumilasci et al., 2006; Fereshtehnejad et al., 2017). 
Dopamine has been shown to modulate salivary secretion (Bagheri et al., 1999; 
Tumilasci et al., 2006; Fereshtehnejad et al., 2017). Levodopa stimulates 
salivary flow and leads to an excessive amount of saliva. Saliva production 
correlates significantly with levodopa dosage and xerostomia or drooling symp-
toms (Proulx et al., 2005). The prevalence of sialorrhea in PD patients ranges 
widely, from 10% to 84% (Srivanitchapoom et al., 2014; Bruno et al., 2016). 
Our study showed that PD patients with drooling were statistically more often 
on levodopa treatment, supporting the findings by Ou et al. (2015). 
Few studies have shown a relation between drooling and motor subtypes of 
the disease (Karakoc et al., 2016). Our study revealed that PD patients with a 
tremor-dominant subtype of the disease reported drooling less frequently than 
those with an akinetic-rigid and PIGD-dominant subtype of PD, which may be 
explained by the more prominent hypokinesia of swallowing musculature in 
patients with these clinical subtypes. 
There are no data from earlier studies on BNT-A treatment and saliva com-
position or microbial changes. Our results on at-rest saliva formation time 
shortened, but it did not overcome statistically a critical value of > 60 sec, 
showing that the oral cavity remained hydrated and healthy during the treatment 
with BNT-A. Saliva’s normal pH is considered 6.7–7.4 (Hand et al., 2014). 
There is a higher risk for dental caries in an acidic oral pH state, and a higher 
risk for the dental calculus in an alkaline pH condition (Dawes, 2007). We did 
not find significant alterations in salivary pH after the BNT-A injections but 
revealed an increase in buffering capacity during the study period, indicating an 
improvement in salivary defence ability that could be related to saliva flow 
decrease and mouth closure. 
 
 
6.6. Strengths and limitations of the study 
The strengths of this research were its broad approach and comprehensive 
examination of sialorrhea patients, including neurological testing and charac-
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terization of salivary parameters. Patients with different neurological disorders 
with childhood, adult and geriatric sialorrhea were included. 
Study III also contains the comparison of salivary parameters between patients 
with neurological diseases, and controls. Saliva characteristics were measured 
both in patients with neurological diseases and controls, and also compared 
between PD patients treated with BNT-A injections or those who were not. 
Dynamic changes after the treatment were followed as well. 
The main limitation of the study is the relatively small sample size of the 
study groups, which might be a source of low statistical reliability. Another 
limitation is the focus only on S. mutans and Lactobacilli of cariogenic micro-
flora and not on other periodontal pathogens that may also influence the oral 
environment. 
 
 
6.7. Practical implications and future perspectives 
According to this study, BNT-A injections are an effective, well-tolerated, and 
low-risk procedure in the treatment of sialorrhea. Most of the more frequent 
complications of this treatment are related to swallowing disturbances, which 
ware off in a matter of weeks. During the study, a pattern for dosage and spe-
cified target point selection were performed and the reinjection schedule was 
arranged, in addition to treating the clinical aspects of sialorrhoea in neuro-
logical diseases that have been described. With these findings we can confirm 
that BNT-A intrasalivary gland injections are beneficial and this treatment 
improves the self estimated quality of life of CP, PD and ALS patients with 
sialorrhea. 
Also, possible complications of BNT-A injections were studied, including 
their impact on microflora and possible role for the oral health, specially to 
development of caries, which is of high practical importance. Our study was 
focused on Lactobacilli and S. mutans but periodontal pathogens need further 
study. 
Also cost-effectiveness studies are of importance as BNT-A injections are 
expensive, and in some cases, e.g. for children, general anesthesia is needed. 
Compared to BNT-A injections, surgery has higher risk of complications, but 
despite of that it has been the treatment of choice for sialorrhea because of 
permanent effect (Delsing et al., 2016; Ozturk et al., 2017). Anticholinergic 
drugs are not so practicable because they may cause a thickening of mucous 
secretion also in lungs as a dangerous complication and are contraindicated in 
the presence of heart diseases, glaucoma, pyloric stenosis, prostatic hyper-
trophy, and hepatic or renal insufficiency (Banfi et al., 2015; Lakraj et al., 
2013). 
Generally, this study has provided the practical implications of the clinical 
management of sialorrhoea by developing the procedure for BNT-A injections 
in salivary glands in order to treat sialorrhoea in patients with chronic 
neurological diseases. 
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7. CONCLUSIONS 
BNT-A injections into the salivary glands to treat drooling is an effective and 
safe method if done under sonographic guidance. It is a good therapeutic option 
for treatment of sialorrhea in different neurological diseases like CP, PD and 
ALS, to improve patients’ quality of life. 
1. Sialorrhea is influenced by different clinical factors like lip seal, head 
position, control of voluntary movement functions, above all tongue, and 
psychological maturity. 
2. Our findings in Study II showed that BNT-A provides a favorable thera-
peutic effect with improvement in saliva’s buffering capacity without com-
promising salivary pH and microflora. Bilateral percutaneous sonography-
guided intrasalivary BNT-A injections into the parotid and submandibular 
glands effectively reduced drooling while maintaining oral health. 
3. The results of Study II did not demonstrate changes in oral health but the 
results of Study III showed a statistically significant increase in levels of 
Lactobacilli, which is a possible risk factor for caries. BNT-A injections can 
effectively treat sialorrhea, but the change of oral microflora has to be taken 
into consideration and patients should be under dentists’ care more fre-
quently. 
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SUMMARY IN ESTONIAN 
Kesknärvisüsteemi haigusest tingitud sialorröa ravi 
botulismitoksiiniga 
Liigset süljeeritust ehk sialorröad võib esineda mitmete kesknärvisüsteemi hai-
guste korral, sh laste tserebraalparalüüs, amüotroofne lateraalskleroos ja Parkin-
soni tõbi (Gonzalez, L. et al., 2017; Odachi et al., 2017). Neuroloogiliste 
haigustega patsientide probleem ei ole seotud mitte niivõrd sülje rohkusega, 
kuivõrd neelamisfunktsiooni häirega. Pideva süljevooluse tõttu on häiritud 
artikulatsioon ja efektiivne kommunikatsioon. Sialorröa on tingitud neelu, 
suupõhja, keele ja suulae lihaste pareesist, hüpokineesiast või düskoordinat-
sioonist (Meece et al., 2010). Osadel patsientidel nõrgeneb köharefleks ja 
seetõttu võib neil esineda sisse hingates suurenenud risk süljeaspiratsiooniks, 
mistõttu võib tekkida aspiratsioonipneumoonia; samuti võib tekkida naha 
matseratsioon. Nende komplikatsioonide tõttu langeb nii patsientide kui ka 
nende hooldajate elukvaliteet (Gonzalez, L. et al., 2017). 
Alates 1980. aastatest on botulismitoksiini kasutatud mitmete kesknärvi-
süsteemi haiguste ravis: peamiselt fokaalsete düstooniate ja spastilisuse leeven-
damiseks. Uue näidustusena on lisandunud botulismitoksiin A (BNT-A) süsti-
mine liigse süljevooluse vähendamiseks hüpersalivatsiooni korral (Rallmann et 
al., 2016; Zhang et al., 2017; Al-Fouzan et al., 2017). 
 
Botulismitoksiini toime 
Botulismi tekitaja, Clostridium botulinum’i produtseeritud toksiin toimib 
perifeerses kolinergilises süsteemis, blokeerides atsetüülkoliini vabanemist pre-
sünaptilistelt närvilõpmetelt ning põhjustades neuromuskulaarset või neuroglan-
dulaarset pöörduvat paralüüsi (Awan, 2017). Süljeerituse vähendamine ja suu-
kuivus on üks botulismitoksiini mõjudest ja seda kasutatakse liigse süljeerituse 
ravis. Terapeutilistel eesmärkidel kasutatakse põhiliselt A-alatüübi toksiini 
(Bentivoglio et al., 2015), toime kestvuseks on märgitud kaks kuni kaheksa 
kuud (Meece et al., 2010). Enamasti manustatakse BNT-A-d nii kõrvasülje-
näärmetesse kui ka submandibulaarsetesse näärmetesse, kuid on kasutatud ka 
süstimist ainult submandibulaarnäärmetesse (Fuster-Torres et al., 2007). 
Varasemad uuringud on kirjeldanud BNT-A ravi positiivset mõju sülje-
erituse pärssimisele, kuid suuõõne tervist käsitlevaid uuringuid on vähe (Pei-
Hsuan et al., 2011). Sülje koguse vähenemine võib mõjutada suuõõne mikro-
floorat ja sülje omadusi (nt pH ja puhvervõime), mistõttu süljevoolu langus võib 
olla seotud pH ja isepuhastumisvõime vähenemisega suuõõnes ning hamba-
kaariese sagenemisega (Sharma et al., 2012). Sülje pH-l ja kariogeensete bakte-
rite hulgal (S. mutans ja laktobatsillid) on suuõõnetervise seisukohalt võtmeroll 
(Pienihäkkinen et al., 1995). S. mutans on oluline hambakaariese tekkes ja 
progressioonis ning seda mikroobi peetakse bakteriaalse kaariese esmaseks 
põhjustajaks. Ta esineb hamba pinnale kinnitunud katus ja kasutab elutege-
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vuseks suhkruid, mille ümbertöötlemise tulemusena tekivad hambaemaili 
lagundavad happed. S. mutans’i esinemine mikroflooras näitab suurenenud riski 
hambakaariese tekkeks (Fejerskov et al., 2008). 
 
Uuringu eesmärgid 
Hinnata BNT-A efektiivsust ja ohutust sialorröa ravis kesknärvisüsteemi hai-
gustega patsientidel. 
1. Hinnata kliiniliste faktorite rolli tserebraalparalüüsiga laste sialorröa puhul. 
2. Hinnata BNT-A süstide mõju suuõõnetervisele sialorröa patsientidel. 
3. Hinnata ja võrrelda sülje koostist ja suuõõne mikrofloora muutumist pärast 
BNT-A süstimist süljenäärmetesse ultraheli kontrolli all sialorröa ravis. 
 
Metoodika  
Uuringu esimene osa hõlmas 12 tserebraalparalüüsiga last Tartu Ülikooli Kliini-
kumi lasteneuroloogia osakonnast, kellest 9 (4 poissi ja 5 tüdrukut vanuses 1,6–
11 aastat) osalesid uuringus täies mahus. Uuringu teine osa hõlmas 20 
sialorröaga täiskasvanut Tartu Ülikooli Kliinikumi näo-lõualuudekirurgia 
osakonnast (12 meest ja 8 naist), keskmise vanusega 63,2 aastat. Uuringu 
kolmandas osas uuriti 38 Parkinsoni tõvega patsienti Tartu Ülikooli Kliinikumi 
neuroloogia ja näo-lõualuudekirurgia osakonnast (16 naist ja 22 meest), kelle 
keskmine vanus oli 71,1 aastat. Patsientide skriininguks kasutati MDS-UPDRS 
küsimustiku igapäevaelu mittemotoorsete aspektide osa (Goetz et al., 2008). 
Uuritavad jagati kolme rühma: (1) 12 Parkinsoni tõvega patsienti (9 meest ja 
3 naist keskmise vanusega 71,3 aastat), kes said liigse süljeerituse raviks  
BNT-A süste; (2) 13 Parkinoni tõvega patsienti (7 meest ja 6 naist keskmise 
vanusega 71,5 aastat) ilma BNT-A ravita; (3) 13 samaealist tervet vabatahtlikku 
kontrollrühmana (6 meest ja 7 naist keskmise vanusega 70,6 aastat). 
Ohutuse eesmärgil süstiti BNT-A-d süljenäärmetesse ultraheli kontrolli all; 
süstiti mõlema poole lõuaaluseid- ja kõrvasüljenäärmeid. BNT-A (Abobotu-
linumi/ Dysport®) doos arvutati patsientide kehakaalu järgi, kogudoosiga 
6 TÜ/kg. 
BNT-A-ga tehtud ravi efektiivsust hinnati intervjuu ja küsimustiku abil enne 
BNT-A süstimist süljenäärmetesse ja pärast süstimist kahenädalaste vahedega 
kuue kuu jooksul. Intervjuu hõlmas haiguse kulgu, sialorröa põhjust, sülje 
hulka, süljelappide vahetuse hulka, aspiratsiooni sagedust, hingamisprobleeme 
ja teisi komplikatsioone ning elukvaliteeti. Teises ja kolmandas uuringu osas 
kasutati MDS-UPDRS küsimustikku (igapäevaelu mittemotoorsed aspektid) ja 
sülje parameetrite mõõtmist; patsiente hinnati enne BNT-A süstimist süljenäär-
metesse ja üks kuu hiljem. Mõõdetavad põhiparameetrid olid suuõõnest kogu-
tud sülje hulk, koostis ja mikrobioloogiline seisund. Uuriti nii puhkeaja kui ka 
stimuleeritud sülge: puhkeaja sülge hinnati märgumise aja, konsistentsi ja pH 
järgi; stimuleeritud sülge hinnati koguse ja puhvervõime järgi. Sülje koostist 
analüüsiti, kasutades Saliva-Check BUFFER in vitro testi (GC EUROPE N.V. 
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B-3001 Leuven, Belgium). Kariogeensete mikroobide uurimiseks kasutati 
Dentocult SM ja Dentocult LB teste (Orion Diagnostica Co Ltd, Epsom, Finland). 
 
Uuringu tulemused ja arutelu 
BNT-A süstimise järel vähenes süljevoolus tserebraalparalüüsiga lastel subjek-
tiivselt juba esimesel nädalal. Kui süstimiseelses seisundis oli süljeeritus väga 
intensiivne (väga intensiivne võrdus skaalal viie punktiga), siis kahe nädala 
möödudes hinnati seda keskmiseks (keskmine võrdus kolme punktiga). Sülje-
lappide arv ja aspiratsioonivajadus vähenes poole võrra. Maksimaalne raviefekt 
esines kahest nädalast kahe kuuni. Ühel lapsel üheksast positiivset efekti ei 
olnud, kuna komplikatsioonina esines neelamisraskus. Elukvaliteet paranes 
oluliselt kaheks kuuks. 
Teise uuringu tulemused näitasid, et 95%-l sialorröa patsientidest oli kuu 
aega hiljem sülje hulk vähenenud, kui BNT-A-d oli süstitud süljenäärmetesse, 
seejuures sülje pH, puhvervõime ja sülje laktobatsillide ja S. mutans’i tase 
statistiliselt olulist muutust ei näidanud (p>0,05). Stimuleeritud sülje hulk 
vähenes oluliselt, olles enne süstimist 7,1 (±5,6) ml ja üks kuu pärast süstimist 
4,5 (±3,4) ml. Puhkeaja sülje teke aeglustus, olles enne süstimist 20,7 (±15,1) 
sekundit ja üks kuu pärast süstimist 34,3 (±19,7) sekundit. 
Kolmanda uuringu tulemused, mis hõlmasid ainult Parkinsoni tõvega 
patsiente, erinesid mõnevõrra teise uuringu tulemustest, kuhu olid kaasatud eri-
neva geneesiga sialorröahaiged. Võrreldes süstimise-eelse tulemusega esinesid 
üks kuu pärast süstimist statistiliselt olulised muutused: viie minuti jooksul 
kogutud sülje hulk vähenes (enne 8,6 (±6,8)ml; 1 kuu pärast 4,8 (±4,1)ml; 
p=0,018) ja puhkeaja sülje teke aeglustus (enne 15 sek; 1 kuu pärast 25sek; 
p=0,05). Puhvervõime oli üks kuu pärast BNT-A süste paranenud võrreldes 
süstimiseelse väärtusega (enne 6,3 (±3,3); 1 kuu pärast 8,8 (±2,8); p=0,037), 
mis näitab sülje paremat võimet normaliseerida oma pH-d pärast sööki. Sülje 
konsistents ja pH ei muutunud oluliselt. Sialorröad esines rohkem hüpo-
kineetilis-rigiidse alatüübiga Parkinsoni tõve patsientidel, samuti ilmnes seos 
pikaajalise levodopa kasutamise ja liigse süljeerituse vahel. 
BNT-A ravi ei muutnud S. mutans’i taset süljes, kuid siiski esines statisti-
liselt oluline laktobatsillide tõus, mis näitab kaariese tekke riski. Samas, perio-
dontaalhaiguste tekke seisukohalt on varasemate uuringutega tõestatud, et lakto-
batsillide osakaalu suurenemine vähendab igemehaigusi tekitavate patogeenide 
osakaalu suuõõnes (Imran et al., 2015). 
 
Järeldused 
BNT-A süstid on efektiivsed krooniliste neuroloogiliste haigustega esineva 
sialorröa ravis, kuid arvesse tuleb võtta suuõõne mikrofloora muutumise riski ja 
sülje hulga vähenemisest tingitud sülje isepuhastumisvõime langust, mis võib 
kaasa tuua kaariese esinemissageduse tõusu. 
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